<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006650.pub5" GROUP_ID="GYNAECA" ID="377207011012341743" MERGED_FROM="" MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.9&lt;/p&gt;&lt;p&gt;Old title: Treatment of venous thromboembolism in cancer patients (Copy excluded studies from ths version to the other 2 reviews)&lt;br&gt;Old title: Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer&lt;/p&gt;" NOTES_MODIFIED="2014-06-25 14:12:16 +0100" NOTES_MODIFIED_BY="Gail Quinn" REVIEW_NO="L002" REVMAN_SUB_VERSION="5.3.2 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop">
<TITLE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer</TITLE>
<CONTACT MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop"><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop"><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="z1404081114197651019260336524884" ROLE="AUTHOR"><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Kahale</LAST_NAME><POSITION>Clinical Epidemiology Unit</POSITION><EMAIL_1>lk45@aub.edu.lb</EMAIL_1><EMAIL_2>lara.kahale@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="02168E4582E26AA201A256C7D0473398" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maddalena</FIRST_NAME><LAST_NAME>Barba</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>maddalena.barba@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Division of Medical Oncology B - Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 (06) 52665419</PHONE_1></ADDRESS></PERSON><PERSON ID="17354" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ignacio</FIRST_NAME><LAST_NAME>Neumann</LAST_NAME><POSITION>Instructor</POSITION><EMAIL_1>ignacio.neumann@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Evidence Based Health Care Program</DEPARTMENT><ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION><ADDRESS_1>Lira 44, Santiago</ADDRESS_1><CITY>Santiago</CITY><REGION>Región metropolitana</REGION><COUNTRY CODE="CL">Chile</COUNTRY><PHONE_1>+56 2 2880965</PHONE_1><FAX_1>+56 2 2897638</FAX_1></ADDRESS></PERSON><PERSON ID="03997437205261125180110308140555" ROLE="AUTHOR"><FIRST_NAME>Nawman</FIRST_NAME><LAST_NAME>Labedi</LAST_NAME><EMAIL_1>nrlabedi@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>State University of New York at Buffalo</ORGANISATION><ADDRESS_1>ECMC CC-142</ADDRESS_1><ADDRESS_2>462 Grider Street</ADDRESS_2><CITY>Buffalo</CITY><ZIP>14215</ZIP><REGION>NY</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="1047AF4182E26AA2005EBC6E53216EA1" ROLE="AUTHOR"><FIRST_NAME>Irene</FIRST_NAME><LAST_NAME>Terrenato</LAST_NAME><EMAIL_1>terrenato@ifo.it</EMAIL_1><ADDRESS><DEPARTMENT>Biostatistics-Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0652 66 66 67</PHONE_1></ADDRESS></PERSON><PERSON ID="10402FB382E26AA2005EBC6E34E65A73" ROLE="AUTHOR"><FIRST_NAME>Francesca</FIRST_NAME><LAST_NAME>Sperati</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>sperati@ifo.it</EMAIL_1><ADDRESS><DEPARTMENT>Biostatistics-Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0652 66 6249</PHONE_1></ADDRESS></PERSON><PERSON ID="553A6CF482E26AA20129AA217ABDC549" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paola</FIRST_NAME><LAST_NAME>Muti</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>muti@mcmaster.ca</EMAIL_1><MOBILE_PHONE>+39 329 574 6405</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>National Cancer Institute Regina Elena</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="18105" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Holger</FIRST_NAME><LAST_NAME>Schünemann</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>schuneh@mcmaster.ca</EMAIL_1><URL>http://www.fhs.mcmaster.ca/ceb/inside_intro.htm</URL><MOBILE_PHONE>+19055375599</MOBILE_PHONE><ADDRESS><DEPARTMENT>Departments of Clinical Epidemiology and Biostatistics and of Medicine</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 4K1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 24931 (assistant)</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop">
<UP_TO_DATE>
<DATE DAY="9" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="2" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop"><DATE DAY="11" MONTH="2" YEAR="2015"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>



</WHATS_NEW>
<HISTORY MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="25" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Table format update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="4" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Data abstraction verified and detailed statistical data included as appendix</P>
<P>Data reanalyzed by using a complete case analysis approach for the primary meta-analysis</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-11 12:31:44 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="9" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Search Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-04-21 11:00:10 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Author contact details amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-28 15:47:33 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="9" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Search updated 7 February 2010. One new RCT was identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-28 15:47:25 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="9" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>One new randomized controlled trial (RCT) identified and added to review. New authors also added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-02-18 21:45:07 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>State University of New York at Buffalo, Department of Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Italian National Cancer Institute Regina Elena Rome</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-04 12:18:08 +0100" MODIFIED_BY="Gail Quinn">
<SUMMARY MODIFIED="2014-06-04 12:14:35 +0100" MODIFIED_BY="Gail Quinn">
<TITLE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">Blood thinners for the long-term treatment of blood clots in patients with cancer</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-04 12:14:35 +0100" MODIFIED_BY="Gail Quinn">
<P>
<B>Background</B>
</P>
<P>Patients with cancer are at an increased risk of developing blood clots and might respond differently to blood thinners (anticoagulants) compared with patients without cancer.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched scientific databases for clinical trials looking at the effects of long-term treatment with different blood thinners on blood clot recurrence in people with cancer with a confirmed diagnosis of deep venous thrombosis (a blood clot in the legs) or pulmonary thrombosis (a blood clot in the lungs). We included trials of adults and children with either solid tumors or blood cancer irrespective of the type of cancer treatment. The trials looked at survival, recurrent blood clot, bleeding, blood platelet levels (which are involved in blood clotting), and postphlebitic syndrome (a complication of long-term blood clots). The evidence is current to February 2013.</P>
<P>
<B>Key results</B>
</P>
<P>We found 10 studies with 1981 patients with cancer. The studies found that low molecular weight heparins (injectable blood thinners) were superior to vitamin K antagonists (oral blood thinners) in reducing the recurrence of blood clots. The available data suggested that both drugs have equal effects on death and the side effect of bleeding.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We were unable to include several possibly relevant studies because the required data were not available. We judged the quality of the evidence for recurrence of blood clots as moderate and the quality of the evidence as low for death and bleeding.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-04 11:04:28 +0100" MODIFIED_BY="Gail Quinn">
<ABS_BACKGROUND MODIFIED="2014-05-08 13:32:30 +0100" MODIFIED_BY="Gail Quinn">
<P>Cancer increases the risk of thromboembolic events in patients including those receiving anticoagulation treatments.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">
<P>To compare the efficacy and safety of low molecular weight heparin (LMWH) and oral anticoagulants for the long-term treatment of venous thromboembolism (VTE) in patients with cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We conducted a comprehensive search for studies of anticoagulation in cancer patients including 1. a February 2013 electronic search of: the Cochrane Central Register of Controlled Trials (CENTRAL Issue 12, 2012), MEDLINE, and EMBASE; 2. a handsearch of conference proceedings; 3. checking of references of included studies; 4. use of the 'related citation' feature in PubMed; and 5. a search of clinicaltrials.gov for ongoing studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We included randomized controlled trials (RCTs) comparing long-term treatment with LMWH versus oral anticoagulants (vitamin K antagonist (VKA) or ximelagatran) in patients with cancer and symptomatic objectively confirmed VTE.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-06-04 11:03:37 +0100" MODIFIED_BY="Gail Quinn">
<P>Using a standardized data form, we extracted data on methodological quality, participants, interventions and outcomes of interest: survival, recurrent VTE, major bleeding, minor bleeding, thrombocytopenia, and postphlebitic syndrome. We assessed the quality of evidence at the outcome level following the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-04 11:04:28 +0100" MODIFIED_BY="Gail Quinn">
<P>Of 9559 identified citations, 10 RCTs (11 reports) were eligible and reported data for 1981 patients with cancer. We excluded 14 studies in which patients with cancer constituted study subgroups, but did not report outcome data for them. Meta-analysis of seven RCTs comparing LMWH with VKA found no statistically significant survival benefit (hazard ratio (HR) 0.96; 95% confidence interval (CI) 0.81 to 1.14) but a statistically significant reduction in VTE (HR 0.47; 95% CI 0.32 to 0.71). The remaining findings did not exclude a beneficial or harmful effect of LMWH compared with VKA for the outcomes of major bleeding (RR 1.07; 95% CI 0.52 to 2.19), minor bleeding (RR 0.89; 95% CI 0.51 to 1.55), or thrombocytopenia (RR 0.98; 95% CI 0.57 to 1.66). We judged the quality of evidence as low for mortality, major bleeding, and minor bleeding, and as moderate for recurrent VTE.</P>
<P>One RCT comparing dabigatran with VKA did not exclude beneficial or harmful effects of one agent over the other. One RCT comparing six months' extension of anticoagulation with 18 months of ximelagatran 24 mg twice daily versus no extended ximelagatran did not exclude beneficial or harmful effects for the outcomes of reduction in VTE, mortality, and minor bleeding. One RCT comparing once-weekly subcutaneous injection of idraparinux for three or six months versus standard treatment (parenteral anticoagulation followed by warfarin or acenocoumarol) suggested a reduction in recurrent VTE (HR 0.39; 95% CI 0.14 to 1.11) at six months, but did not exclude beneficial or harmful effects for the outcomes of mortality (HR 0.99; 95% CI 0.66 to 1.48) and major bleeding (RR 1.04; 95% CI 0.39 to 2.83).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>For the long-term treatment of VTE in patients with cancer, LMWH compared with VKA reduces venous thromboembolic events but not mortality. The decision for a patient with cancer and VTE to start long-term LMWH versus oral anticoagulation should balance the benefits and harms and integrate the patient's values and preferences for the important outcomes and alternative management strategies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-04 12:18:08 +0100" MODIFIED_BY="Gail Quinn">
<BACKGROUND MODIFIED="2014-06-04 12:18:08 +0100" MODIFIED_BY="Gail Quinn">
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> lists a glossary of terms.</P>
<CONDITION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The presence of cancer increases the risk of venous thromboembolism (VTE) four- to six-fold (<LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>). Cancer-related interventions such as chemotherapy, hormonal therapy, and indwelling central venous catheters also increase the risk of VTE (<LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>). Similarly, patients undergoing surgery for cancer have a higher risk of VTE than patients undergoing surgery for benign diseases (<LINK REF="REF-Gallus-1997" TYPE="REFERENCE">Gallus 1997</LINK>; <LINK REF="REF-Kakkar-1970" TYPE="REFERENCE">Kakkar 1970</LINK>). Furthermore, patients with cancer and VTE have a higher risk of death than patients with cancer alone or with VTE alone (<LINK REF="REF-Levitan-1999" TYPE="REFERENCE">Levitan 1999</LINK>; <LINK REF="REF-Sorensen-2000" TYPE="REFERENCE">Sorensen 2000</LINK>).</P>
<P>Patients with cancer also have different benefits and risks from anticoagulant treatment than patients without cancer. For instance, during oral anticoagulation therapy for VTE, patients with cancer, compared with patients without cancer, have a higher incidence of recurrent VTE (27.1 versus 9.0 events per 100 patient-years, P value = 0.003) and of major bleeding (13.3 versus 2.2 events per 100 patient-years, P value = 0.002) (<LINK REF="REF-Hutten-2000" TYPE="REFERENCE">Hutten 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Low molecular weight heparins (LMWHs) do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. These agents constitute indirect anticoagulants as their activity is mediated by plasma cofactors. LMWHs are not absorbed orally and must be administered parenterally by subcutaneous injections (<LINK REF="REF-Hirsh-1993" TYPE="REFERENCE">Hirsh 1993</LINK>).</P>
<P>Vitamin K antagonists (VKA) have been the mainstay of oral anticoagulant therapy since the 1950s. Well-designed clinical trials have shown the effectiveness of VKAs for the primary and secondary prevention of several venous and arterial thrombotic diseases (<LINK REF="REF-Ansell-2008" TYPE="REFERENCE">Ansell 2008</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Several systematic reviews have compared LMWH and VKA in the long-term treatment of VTE, but in populations not restricted to patients with cancer (<LINK REF="REF-Conti-2003" TYPE="REFERENCE">Conti 2003</LINK>; <LINK REF="STD-Iorio-2003" TYPE="STUDY">Iorio 2003</LINK>; <LINK REF="REF-van-der-Heijden-2007" TYPE="REFERENCE">van der Heijden 2007</LINK>). The review by van der Heijden et al. did not complete a preplanned subgroup analysis in patients with cancer as the required data were not specifically reported (<LINK REF="REF-van-der-Heijden-2007" TYPE="REFERENCE">van der Heijden 2007</LINK>). The review by Conti et al. did not conduct a meta-analysis in the subgroup of patients with cancer (<LINK REF="REF-Conti-2003" TYPE="REFERENCE">Conti 2003</LINK>). In the review by Iorio et al., one meta-analysis in the subgroup of patients with cancer found no statistically significant difference in mortality (OR 1.13; 95% CI 0.54 to 2.38).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-04 12:18:08 +0100" MODIFIED_BY="Gail Quinn">
<P>The subgroup analysis in <LINK REF="STD-Iorio-2003" TYPE="STUDY">Iorio 2003</LINK> did not report on the comparative safety of LMWH and VKA (<LINK REF="STD-Iorio-2003" TYPE="STUDY">Iorio 2003</LINK>). The Cochrane Collaboration has recognized that addressing all important outcomes including harm is of great importance to make evidence-based healthcare decisions. The last update of this Cochrane systematic review concluded that the existing evidence suggested a reduction in venous thromboembolic events in patients with cancer but not mortality (<LINK REF="REF-Akl-2011" TYPE="REFERENCE">Akl 2011</LINK>). Since 2011, there have been publications of studies assessing the newer oral anticoagulants, so we aimed to update this systematic review to capture and include any such studies relevant to our question.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>To compare the efficacy and safety of LMWH and oral anticoagulants for the long-term treatment of VTE in patients with cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SELECTION_CRITERIA MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<CRIT_STUDIES MODIFIED="2011-02-17 20:40:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Patients with cancer with a confirmed diagnosis of VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)). Patients could have been of any age group (including children), with either solid or hematologic cancer, at any stage of their cancer, and irrespective of the type of cancer therapy.</P>
<P>DVT should have been diagnosed using one the following objective diagnostic tests: venography, <SUP>125</SUP>I-fibrinogen-uptake test, impedance plethysmography, or Doppler-ultrasound. PE should have been diagnosed using one of the following objective diagnostic tests: pulmonary perfusion/ventilation scans, computed tomography, or pulmonary angiography).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We included studies comparing long-term treatment with LMWH versus oral anticoagulants (VKA or ximelagatran). There should have been no differences in how the study groups were treated besides the main intervention (e.g. the type of initial anticoagulation), that is, studies should have treated patient groups similarly apart from the intervention of interest.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Survival.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Symptomatic recurrent DVT.</LI>
<LI>Symptomatic recurrent PE.</LI>
<LI>Major bleeding.</LI>
<LI>Minor bleeding.</LI>
<LI>Thrombocytopenia.</LI>
<LI>Postphlebitic syndrome.</LI>
</UL>
<P>We accepted the definitions of major bleeding, minor bleeding, thrombocytopenia, and postphlebitic syndrome of the authors of the original studies as long as they were standardized.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<ELECTRONIC_SEARCHES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The search was part of a comprehensive search for studies of anticoagulation in patients with cancer. We conducted the original electronic search in January 2007 and updated it in February 2010 and in February 2013. We electronically searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2012), MEDLINE (1966 onward; accessed via Ovid), EMBASE (1980 onward; accessed via Ovid), and ISI Web of Science (February 2010). The search strategies combined terms relating to the anticoagulants, cancer, and study design. We list the search strategies in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>In addition to the electronic search, we used a number of supplemental search strategies. We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, starting with its first volume, 1982 up to June 2013) and of the American Society of Hematology (ASH, starting with its 2003 issue up to June 2013). We reviewed the reference lists of included papers, relevant papers, and related systematic reviews (<LINK REF="REF-Conti-2003" TYPE="REFERENCE">Conti 2003</LINK>; <LINK REF="REF-van-der-Heijden-2007" TYPE="REFERENCE">van der Heijden 2007</LINK>). We used the 'related citation' feature in PubMed to identify additional papers. We used ISI Web of Science to identify papers citing the landmark studies. We used no language restrictions. We also searched ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">clinicaltrials.gov/</A>) for ongoing studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<STUDY_SELECTION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Two review authors independently screened the title and abstract of identified article citations for potential eligibility. We retrieved the full text of articles judged potentially eligible by at least one review author. Two review authors then independently screened the full-text article for eligibility using a standardized form with explicit inclusion and exclusion criteria (as detailed in the <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK> section). We resolved any disagreements about which articles were eligible by discussion or by consulting a third review author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>For English articles, two review authors independently extracted the data from each study and resolved their disagreements by discussion or by consulting a third review author. For non-English articles, one review author extracted data. The collected data related to the following.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<UL>
<LI>Demographic characteristics (e.g. age, sex).</LI>
<LI>Cancer characteristics (e.g. histologic type, site of origin, stage, time since diagnosis, estimated life expectancy, current cancer treatments, performance status).</LI>
<LI>Whether participants had DVT, PE, or both.</LI>
<LI>Number of patients in each treatment arm.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<UL>
<LI>Type and dosage schedule of LMWH.</LI>
<LI>Intensity of VKA.</LI>
<LI>Dosage schedule of ximelagatran.</LI>
<LI>Type (unfractionated heparin (UFH) versus LMWH versus fondaparinux) and duration of initial anticoagulation.</LI>
<LI>Co-interventions including radiation therapy, chemotherapy, and hormonal therapy (type and duration).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>We extracted both time-to-event data and binary data.</P>
<P>For time-to-event data, we abstracted the log (hazard ratio (HR)) and its variance from trial reports; if these were not reported, we digitized the published Kaplan-Meier survival curves and estimated the log(HR) and its variance using the method of Parmar (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). We also noted the minimum and maximum duration of follow-up, which are required to make these estimates. We performed these calculations in Stata 9, using a specially written program, which yielded the reported log(HR) and variance when used on the data presented in Table V of <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>.</P>
<P>For binary data, we extracted the reported outcome data necessary to conduct intention-to-treat (ITT) analyses. We collected outcome event rates whenever they were reported in each trial. When the authors did not report and could not provide the number of events at specific time points, two biostatisticians estimated these numbers independently and in duplicate from survival curves, if available.</P>
<P>We attempted to contact authors for incompletely reported data. We decided a priori to consider abstracts only if authors supplied us with full reports of their methods and results.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We assessed risk of bias at the study level using The Cochrane Collaboration's 'Risk of bias' tool. Two review authors independently assessed the methodologic quality of each included study and resolved any disagreements by discussion. Methodologic criteria included the following:<BR/>
</P>
<UL>
<LI>adequate sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>patient blinding;</LI>
<LI>provider blinding;</LI>
<LI>data collector blinding;</LI>
<LI>outcome assessor blinding;</LI>
<LI>analyst blinding;</LI>
<LI>percentage followed up and whether incomplete outcome data were addressed;</LI>
<LI>whether the study was free of selective outcome reporting;</LI>
<LI>whether the study was stopped early for benefit;</LI>
<LI>whether the analysis followed the ITT principle.</LI>
</UL>
<P>See section on <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK> about assessing risk of bias associated with participants with missing data.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We collected and analyzed HRs for time-to-event data and risk ratios (RRs) for dichotomous data. None of the outcomes of interest was meta-analyzed as a continuous variable.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-02-17 20:51:18 +0000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="4">Determining participants with missing data</HEADING>
<P>It was not clear whether certain participant categories (e.g. those described as 'withdrew consent' or 'experienced adverse events') were actually followed up by the trialists (versus had missing participant data). To deal with this issue, we made the following considerations:</P>
<UL>
<LI>'ineligible participants', and 'did not receive the first dose' participant categories, which were defined prior to the initiation of the study intervention, most likely had missing participant data;</LI>
<LI>'withdrew consent' and 'lost to follow-up' participant categories, which were defined after the initiation of the study intervention, most likely had missing participant data;</LI>
<LI>'dead', 'experienced adverse events', 'non-compliant', 'discontinued prematurely' (and similarly described) participant categories, less likely had missing participant data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with participants with missing data in the primary meta-analysis</HEADING>
<P>In the primary meta-analysis, we used a complete case analysis approach, that is, we excluded participants considered to have missing data.</P>
<P>For categorical data, we used the following calculations for each study arm:</P>
<UL>
<LI>denominator: (number of participants randomized) - (number of participants most likely with missing data, both pre- and post-intervention initiation);</LI>
<LI>numerator: number of participants with observed events (i.e. participants who suffered at least one event for the outcome of interest during their available follow-up time).</LI>
</UL>
<P>For continuous data, we used for each study arm, the reported mean and standard deviation (SD) for participants actually followed up by the trialists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessing the risk of bias associated with participants with missing data</HEADING>
<P>When the primary meta-analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta-analyses to assess the risk of bias associated with missing participant data. Those sensitivity meta-analyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity meta-analyses were increasingly stringent in order to challenge the statistical significance of the results of the primary analysis progressively (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>; <LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>).</P>
<P>For categorical data and for RR showing a reduction in effect (RR less than 1), we used the following increasingly stringent but plausible assumptions (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>):</P>
<UL>
<LI>for the control arm, relative incidence (RI) among those with missing data (lost to follow-up (LTFU)) compared with those with available data (followed up, FU) in the same arm (RI<SUB>LTFU/FU</SUB>) = 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 1.5;</LI>
</UL>
<UL>
<LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 2;</LI>
<LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 3;</LI>
<LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 5.</LI>
</UL>
<P>For RR showing an increase in effect (RR greater than 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<SUB>LTFU/FU </SUB>= 1 for the intervention arm).</P>
<P>Specifically, we used the following calculations for each study arm:</P>
<UL>
<LI>denominator: (number of participants randomized) - (number of participants most likely with missing data, preintervention initiation);</LI>
<LI>numerator: (number of participants with observed events) + (number of participants most likely with missing data post-intervention initiation, with assumed events).</LI>
</UL>
<P>Assumed events are calculated by applying the a priori plausible assumptions to the participants considered most likely with missing data post-intervention initiation.</P>
<P>For continuous data, we used the four strategies suggested by Ebrahim et al. (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>). The strategies imputed the means for participants with missing data based on the means of participants actually followed up in individual trials included in the systematic review. To impute SD, we used the median SD from the control arms of all included trials. (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>.)</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We assessed heterogeneity between trials by visual inspection of forest plots, estimation of the percentage heterogeneity between trials that cannot be ascribed to sampling variation (I<SUP>2</SUP> statistic) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and by a formal statistical test of the significance of the heterogeneity. If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-02-17 20:56:15 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting bias by trying to identify whether the study was included in a trial registry, whether a protocol was available, and whether the methods section provided a list of outcomes (to assess selective outcome reporting bias). We compared the list of outcomes from those sources to the outcomes reported in the published paper.</P>
<P>We created inverted funnel plots of individual study results plotted against sample size in order to evaluate possible publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We calculated the agreement between the two independent review authors for the assessment of eligibility using the kappa statistic. We analyzed, when possible, both time-to-event data and binary data.</P>
<P>For time-to-event data, we pooled the log(HR) values using a random-effects model and the generic inverse variance facility of Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
<P>For binary data, for a specific outcome, and for each trial, we used the ITT principle to calculate the RR separately for each study. We then pooled the results of the different studies using a random-effects model.</P>
<P>We assessed the quality of evidence at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We evaluated heterogeneity across trials using the I<SUP>2</SUP> statistic, based on the following classification with the value of I<SUP>2</SUP>: 0 to 30 = low; 30 to 60 = moderate and worthy of investigation; 60 to 90 = severe and worthy of understanding; and 90 to 100 = allowing aggregation only with major caution.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We conducted sensitivity analysis by excluding the study of lowest methodologic quality (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>), and then a study that used a different initial anticoagulant in the two study arms (post hoc analysis) (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>).</P>
<P>In addition, when the primary meta-analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta-analyses to assess the risk of bias associated with missing participant data.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<STUDY_DESCRIPTION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SEARCH_RESULTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The February 2013 search strategy identified 9559 citations (after removal of duplicates) from which we removed the results of our January 2010 search. The title and abstract screening of the 9559 unique citations identified 65 as potentially eligible for this review. We included 10 studies (11 reports) and excluded the remaining 54 studies. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the study flow diagram. Agreement between authors for study eligibility was excellent (kappa = 0.94).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>We included 10 RCTs (11 reports) with 1981 patients with cancer for which outcome data were available (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). Nine studies were published in full text (<LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-van-Doormaal-2010" TYPE="STUDY">van Doormaal 2010</LINK>), and one was published as an abstract (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>). Seven RCTs compared a LMWH with a VKA for the long-term treatment of VTE (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>); only one of these studies used a different initial anticoagulant in the two study arms (LMWH in the LMWH group and UFH in the VKA group) (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>). One study compared dabigatran with warfarin for six months (<LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>). One study with a subgroup of patients with cancer compared 18 months of extended treatment with ximelagatran versus placebo, after six months of anticoagulant therapy in patients with cancer (<LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>). One RCT compared a once-weekly subcutaneous injection of idraparinux for three or six months versus standard treatment (tinzaparin, enoxaparin, or dose-adjusted intravenous heparin followed by warfarin or acenocoumarol).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Of the 54 excluded studies, in 14 studies, patients with cancer constituted study subgroups but their outcome data were not available (<LINK REF="STD-Beckman-2003" TYPE="STUDY">Beckman 2003</LINK>; <LINK REF="STD-Das-1996" TYPE="STUDY">Das 1996</LINK>; <LINK REF="STD-Daskalopoulos-2005" TYPE="STUDY">Daskalopoulos 2005</LINK>; <LINK REF="STD-Fiessinger-2005" TYPE="STUDY">Fiessinger 2005</LINK>; <LINK REF="STD-Gonzalez_x002d_Fajardo-1999" TYPE="STUDY">Gonzalez-Fajardo 1999</LINK>; <LINK REF="STD-Hull-2007" TYPE="STUDY">Hull 2007</LINK>; <LINK REF="STD-Hull-2009" TYPE="STUDY">Hull 2009</LINK>; <LINK REF="STD-Kucher-2005" TYPE="STUDY">Kucher 2005</LINK>; <LINK REF="STD-Levine-1995" TYPE="STUDY">Levine 1995</LINK>; <LINK REF="STD-Lopaciuk-1999" TYPE="STUDY">Lopaciuk 1999</LINK>; <LINK REF="STD-Massicotte-2003" TYPE="STUDY">Massicotte 2003</LINK>; <LINK REF="STD-P_x00e9_rez_x002d_de_x002d_Llano-2010" TYPE="STUDY">Pérez-de-Llano 2010</LINK>; <LINK REF="STD-Pini-1994" TYPE="STUDY">Pini 1994</LINK>; <LINK REF="STD-Veiga-2000" TYPE="STUDY">Veiga 2000</LINK>). We excluded the remaining 40 studies for the following reasons: case series (one study), review (15 studies), retrospective (four studies), protocol (two studies), observational (six studies), trial but not randomized and controlled (four studies), no cancer patients included (four studies), only one patient with cancer was included (one study), no relevant outcome (two studies), and not intervention of interest (study compared different duration of interventional drugs) (one study). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows the methodologic quality graph and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows the summary of the quality of the included studies. The methodologic quality varied by outcome. For the comparison of LMWH with VKA, the quality of evidence was low for mortality, major bleeding, and minor bleeding and moderate for recurrent VTE (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<ALLOCATION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The concealment of allocation was adequate in seven trials (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>; <LINK REF="STD-van-Doormaal-2010" TYPE="STUDY">van Doormaal 2010</LINK>), and unclear in the other three (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Three studies blinded patients (<LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>), three studies blinded caregivers (<LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>), three studies blinded data collectors (<LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>), eight studies blinded outcome adjudicators (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-van-Doormaal-2010" TYPE="STUDY">van Doormaal 2010</LINK>), and five studies blinded data analysts (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The percentage follow-up ranged from 89% to 100%.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-02-18 20:40:39 +0000" MODIFIED_BY="[Empty name]">
<P>We did not suspect selective reporting of outcomes for any of the studies except for <LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK> as there was no report on the bleeding events. The cancer subgroup data were missing for a large number of studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Eight studies conducted analysis consistent with the ITT principle (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>; <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>; <LINK REF="STD-van-Doormaal-2010" TYPE="STUDY">van Doormaal 2010</LINK>). This was not clear in two studies (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>). One study was stopped early for benefit (<LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>).</P>
<P>Another potential source of bias is the screening for asymptomatic VTE in three of the nine included studies (<LINK REF="STD-Lopez_x002d_Beret-2001" TYPE="STUDY">Lopez-Beret 2001</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="3">Low molecular weight heparin versus vitamin K antagonist</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Survival</HEADING>
<P>We used time-to-event data reported by two studies (<LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>), and supplied by the author of a third study (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>). The pooled analysis showed no statistically significant survival benefit of LMWH over VKA (HR 0.96; 95% CI 0.81 to 1.14; I<SUP>2</SUP> = 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Three studies reported all-cause mortality at three months (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>; <LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>). The pooled analysis did not exclude clinically significant benefit or harm with LMWH compared with VKA (RR 0.77; 95% CI 0.46 to 1.28; I<SUP>2 </SUP>= 17%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The results were consistent in a sensitivity analysis excluding the study published as an abstract (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>) (RR 0.76; 95% CI 0.37 to 1.55; I<SUP>2</SUP> = 56%), and in a sensitivity analysis excluding the study that used a different initial anticoagulant in the two study arms (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>) (RR 0.51; 95% CI 0.25 to 1.04; I<SUP>2</SUP> = 0%).</P>
<P>Three studies reported all-cause mortality at six months (<LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>). The pooled analysis showed no statistically significant difference between LMWH and VKA (RR 0.96; 95% CI 0.81 to 1.13; I<SUP>2</SUP> = 0%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>We finally pooled data from all studies irrespective of the timing of outcome assessment and using the six-month data from the study by Meyer et al. The pooled analysis showed no statistically significant difference between LMWH and VKA (RR 0.97; 95% CI 0.84 to 1.11; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The results were consistent in a sensitivity analysis excluding the study published as an abstract (<LINK REF="STD-Cesarone-2003" TYPE="STUDY">Cesarone 2003</LINK>) (RR 0.97; 95% CI 0.85 to 1.10; I<SUP>2</SUP> = 0%), and in a sensitivity analysis excluding the study that used a different initial anticoagulant in the two study arms (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>) (RR 0.97; 95% CI 0.84 to 1.11; I<SUP>2</SUP> = 0%).</P>
<P>The inverted funnel plot for the outcome of all-cause mortality did not suggest publication bias (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrent venous thromboembolism</HEADING>
<P>We used time-to-event data reported by two studies (<LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>), and supplied by the author of a third study (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>). The pooled analysis showed a statistically significant benefit of LMWH over VKA (HR 0.47; 95% CI 0.32 to 0.71; I<SUP>2</SUP> = 0%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The results were consistent in a binary data analysis including five studies (RR 0.50; 95% CI 0.35 to 0.71; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) (<LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>; <LINK REF="STD-Romera-2009" TYPE="STUDY">Romera 2009</LINK>), and a sensitivity analysis excluding the study that used a different initial anticoagulant in the two study arms (RR 0.51; 95% CI 0.35 to 0.76; I<SUP>2</SUP> = 0%) (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>).</P>
<P>Since the primary meta-analysis found a statistically significant effect, and in order to assess the risk of bias associated with missing participant data, we conducted sensitivity meta-analyses using the a priori plausible assumptions detailed in the methods section. The effect estimate remained statistically significant even when using the most stringent plausible assumption (RR 0.53; 95% CI 0.38 to 0.75).</P>
<P>None of the studies reported DVT and PE as separate outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bleeding outcomes</HEADING>
<P>Four studies assessed bleeding outcomes (<LINK REF="STD-Deitcher-2006" TYPE="STUDY">Deitcher 2006</LINK>; <LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>). The pooled analysis did not exclude a beneficial or harmful effect of LMWH compared with VKA for major bleeding (RR 1.07; 95% CI 0.52 to 2.19; I<SUP>2 </SUP>= 46%) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>) or minor bleeding (RR 0.89; 95% CI 0.51 to 1.55; I<SUP>2 </SUP>= 77%) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The results were consistent in a sensitivity analysis excluding the study that used a different initial anticoagulant in the two study arms for the outcomes of minor bleeding (RR 0.80; 95% CI 0. 37 to 1.73; I<SUP>2 </SUP>= 84%) and major bleeding (RR 1.13; 95% CI 0.39 to 3.31; I<SUP>2</SUP> = 64%) (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Thrombocytopenia</HEADING>
<P>Two studies assessed thrombocytopenia as an outcome (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>; <LINK REF="STD-Meyer-2002" TYPE="STUDY">Meyer 2002</LINK>). The pooled analysis did not exclude a beneficial or harmful effect of LMWH compared with VKA (RR 0.98; 95% CI 0.57 to 1.66; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The results were consistent in a sensitivity analysis excluding the study that used a different initial anticoagulant in the two study arms (RR 0.89; 95% CI 0.49 to 1.60) (<LINK REF="STD-Hull-2006" TYPE="STUDY">Hull 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Postphlebitic syndrome</HEADING>
<P>None of the studies reported postphlebitic syndrome as an outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dabigatran versus warfarin</HEADING>
<P>We obtained outcome data for the cancer subgroup directly from the authors. The study by <LINK REF="STD-Schulman-2009" TYPE="STUDY">Schulman 2009</LINK> did not exclude a beneficial or harmful effect with dabigatran compared with warfarin with respect to mortality (RR 0.89; 95% CI 0.30 to 2.61), recurrent VTE (RR 0.59; 95% CI 0.10 to 3.43), major bleeding (RR 1.48; 95% CI 0.37 to 5.94), and thrombocytopenia (RR 6.25; 95% CI 0.33 to 118.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extended ximelagatran versus no extended ximelagatran</HEADING>
<P>We obtained outcome data for the cancer subgroup directly from the authors. Following initial anticoagulant treatment for six months, 18 months' extended treatment with ximelagatran 24 mg twice daily did not exclude a beneficial or harmful effect for the ourcomes of reduction in VTE (RR 0.47; 95% CI 0.04 to 4.94), mortality (RR 1.41; 95% CI 0.25 to 7.91), or minor bleeding (RR 1.08; 95% CI 0.44 to 2.62) (<LINK REF="STD-Schulman-2003" TYPE="STUDY">Schulman 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Idraparinux versus standard anticoagulation therapy</HEADING>
<P>The study by <LINK REF="STD-van-Doormaal-2010" TYPE="STUDY">van Doormaal 2010</LINK> compared once-weekly subcutaneous injection of idraparinux for three or six months versus standard treatment (parenteral anticoagulation followed by warfarin or acenocoumarol). The reported findings suggested a reduction in recurrent VTE (HR 0.39; 95% CI 0.14 to 1.11) at six months, but did not exclude beneficial or harmful effects for the outcomes of mortality (HR 0.99; 95% CI 0.66 to 1.48) and major bleeding (RR 1.04 95% CI 0.39 to 2.83).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SUMMARY_OF_RESULTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>For the long-term treatment of VTE in patients with cancer, LMWH compared with VKA provided no statistically significant survival benefit but a statistically and patient important reduction in VTE. The findings did not exclude a beneficial or harmful effect of LMWH compared with VKA in terms of bleeding outcomes or thrombocytopenia. For dabigatran compared with warfarin, a beneficial or harmful effect on mortality, major bleeding, and thrombocytopenia could also not be excluded. Extended treatment with ximelagatran following six months of anticoagulant therapy could not be exclude a beneficial or harmful effect on reduced VTE, mortality, and minor bleeding d. For once-weekly subcutaneous injection of idraparinux compared with standard treatment, the findings suggested a reduction in recurrent VTE, but did not exclude beneficial or harmful effects for the outcomes of mortality and bleeding.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>While the reduction in venous thromboembolic events with LMWH is expected to reduce thrombosis-related mortality, this did not translate into an observed reduction in all-cause mortality. This finding is not apparently explained by an increase in any specific-cause mortality (e.g. fatal bleeding), but might be due to the lack of power to detect a reduction in all-cause mortality. Similarly, the size of the available evidence was not large enough to rule out beneficial or harmful effects for many comparisons (e.g. effects of LMWH versus VKA on bleeding, effects of dabigatran versus VKA on all outcomes).</P>
<P>We were unable to conduct subgroup analyses based on histologic type or stage of cancer because of the lack of data. In the absence of evidence for the contrary, we assume that the results of this study apply to patients with any type or stage of cancer.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>For the comparison of LMWH versus VKA, the pooled results for bleeding outcomes (LMWH versus VKA comparison) showed moderate to severe heterogeneity. Unfortunately, the number of pooled studies was relatively small to allow us to explore the causes of heterogeneity by conducting subgroup analyses. We judged the quality of evidence as low for mortality, major bleeding, and minor bleeding, and moderate for recurrent VTE (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Our systematic approach to searching, study selection, and data extraction should have minimized the likelihood of missing relevant studies. This increases the confidence in the internal validity of our findings. A major limitation of this review is that we were unable to include in the meta-analyses 11 eligible RCTs with subgroups of patients with cancer because relevant data were not reported and not obtainable from the authors. However, the inverted funnel plot for the outcome of all-cause mortality did not suggest publication bias. This suggests that the treatment effect from those 11 RCTs should be similar to the one estimated from the included studies. One has to keep in mind that funnel plots have limited power to detect bias if the number of studies is small (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Of the three published systematic reviews comparing LMWH and VKA in the long-term treatment of VTE (<LINK REF="REF-Conti-2003" TYPE="REFERENCE">Conti 2003</LINK>; <LINK REF="STD-Iorio-2003" TYPE="STUDY">Iorio 2003</LINK>; <LINK REF="REF-van-der-Heijden-2007" TYPE="REFERENCE">van der Heijden 2007</LINK>), only the study by Iorio et al. conducted a meta-analysis in the subgroup of patients with cancer and found no statistically significant difference in mortality (OR 1.13; 95% CI 0.54 to 2.38). This finding is consistent with the results of our meta-analysis.</P>
<P>Two of the three systematic reviews showed no statistically significant reduction of recurrent VTE by LMWH compared with VKA when the meta-analysis was not restricted to patients with cancer (<LINK REF="STD-Iorio-2003" TYPE="STUDY">Iorio 2003</LINK>; <LINK REF="REF-van-der-Heijden-2007" TYPE="REFERENCE">van der Heijden 2007</LINK>). However, our meta-analysis showed a significant reduction in recurrent VTE in patients with cancer. The reason for this possible differential effect in patients with cancer is not clear.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>The decision for a patient with cancer and venous thromboembolism (VTE) to start long-term low molecular weight heparin (LMWH) versus oral anticoagulation should balance the benefits and harms and integrate the patient's values and preferences for outcomes and management options (<LINK REF="REF-Haynes-2002" TYPE="REFERENCE">Haynes 2002</LINK>). While LMWH decreases the incidence of VTE and possibly of death, it might be more costly and less acceptable because of its subcutaneous route of administration.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Future research should compare LMWH versus other anticoagulants such as ximelagatran and fondaparinux. There is also a need for research assessing patients' values and preferences regarding long-term anticoagulant agents for treating VTE. Researchers should consider making the raw data from randomized controlled trials (RCTs) available for individual patient data meta-analysis. Further RCTs including subgroups of patients with cancer should report separate results for these subgroups.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-06-04 10:29:37 +0100" MODIFIED_BY="Gail Quinn">
<P>We thank Dr. Buller, Dr. Deitcher, Dr. Harenberg, Dr. Huisman, Dr. Hull, Dr. Prandoni, Dr. Reomera, Dr. Schulman, and Dr. Siragusa for their assistance. We thank Ms. Ann Grifasi for her administrative support.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group.</P>
<P>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>HJS: no personal payments from for-profit sponsors related to the subject matter since 2010. EAA and HJS are members of the executive committee of the American College of Chest Physicians' Antithrombotic Therapy Guidelines.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-06-04 10:29:11 +0100" MODIFIED_BY="Gail Quinn">
<P>EAA: protocol development, search for trials, screening, data extraction, data analysis, manuscript drafting, review co-ordination.LK: screening, data extraction, data analysis.MB: data extraction, data analysis.IN: screening.NL: data abstraction, manuscript drafting.SR: screening, data extraction.IT: screening, data extraction.FS: screening, data extraction.PM: data analysis, methodologic advice.HJS: protocol development, search for trials, data extraction, data analysis, methodologic advice.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<STUDIES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<INCLUDED_STUDIES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Cesarone-2003" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Cesarone 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Ledda A, Nicolaides A, Belcaro G, Geroulakos G</AU>
<TI>Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>108</VL>
<NO>17</NO>
<PG>2875</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deitcher-2006" NAME="Deitcher 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Deitcher S, Kessler C, Lyons R, Fareed J. Treatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Blood. 2003 San Diego, California, 2003;102(11 (Pt 1)):322a.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J, Oncenox Investigators</AU>
<TI>Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period</TI>
<SO>Clinical &amp; Applied Thrombosis/Hemostasis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>389-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2006" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Hull 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Hull R. A randomized trial evaluating long-term low-molecular weight heparin therapy for threemonths vs. intravenous heparin followed by warfarin sodium in three patients with current cancer. Journal of Thrombosis &amp;amp; Haemostasis. 2003 July;1 (Suppl 1):12-8.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R et al</AU>
<TI>Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer</TI>
<SO>American Journal of Medicine</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>12</NO>
<PG>1062-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2003" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Lee 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Lee A, Levine M, Baker R, Bowden C, Kakkar A, M P, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. The New England journal of medicine. 2003 Jul;349(2):146-53.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee A, Levine M, Baker R, Bowden C, Kakkar AK, Prins M et al</AU>
<TI>Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>2</NO>
<PG>146-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C et al</AU>
<TI>Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>10</NO>
<PG>2123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Beret-2001" MODIFIED="2014-05-23 14:19:46 +0100" MODIFIED_BY="Anne Lawson" NAME="Lopez-Beret 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G et al</AU>
<TI>Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>1</NO>
<PG>77-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2002" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Meyer 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.[see comment]. Archives of Internal Medicine. 2002 Aug 12-26;162(15):1729-35.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P et al</AU>
<TI>Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<NO>15</NO>
<PG>1729-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romera-2009" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Romera 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romera A, Cairols MA, Vila-Coll R, Martí X, Colomé E, Bonell A et al</AU>
<TI>A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>3</NO>
<PG>349-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2003" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Schulman 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, Investigators TI, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.[see comment]. New England Journal of Medicine. 2003 Oct 30;349(18):1713-21.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, Investigators TI et al</AU>
<TI>Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>18</NO>
<PG>1713-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2009" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Schulman 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al</AU>
<TI>Dabigatran versus warfarin in the treatment of acute venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<PG>2342-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Doormaal-2010" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="van Doormaal 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M et al</AU>
<TI>Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Altschuler-1990" NAME="Altschuler 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Altschuler E, Moosa H, Selker R, Vertosick FJ. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors.[see comment]. Neurosurgery. 1990 Jul;27(1):74-6; discussion 7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altschuler E, Moosa H, Selker R, Vertosick FJ</AU>
<TI>The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors</TI>
<SO>Neurosurgery</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>1</NO>
<PG>74-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrea-2003" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Andrea 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Andrea N, Ansell J. Management of thrombosis in the cancer patient.The Journal of Supportive Oncology. 2003;1(4):235-8&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrea N, Ansell J</AU>
<TI>Management of thrombosis in the cancer patient</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>4</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Astermark-1998" NAME="Astermark 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Astermark J, Bjorgell O, Linden E, Lethagen S, Nilsson P, Berntorp E. Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation. Journal of Internal Medicine. 1998 Jul;244(1):79-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Astermark J, Bjorgell O, Linden E, Lethagen S, Nilsson P, Berntorp E</AU>
<TI>Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1998</YR>
<VL>244</VL>
<NO>1</NO>
<PG>79-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beckman-2003" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Beckman 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis &amp;amp; Haemostasis. 2003;89(6):953-8.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:56 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ</AU>
<TI>Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>89</VL>
<NO>6</NO>
<PG>953-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bona-1997" NAME="Bona 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Bona R, Wallace D, Hickey A, Wajcs S. Thrombin generation and activity are increased in patients with cancer receiving sodium warfarin as secondary prophylaxis against venous thrombosis. Blood. 1997 Nov 15;90(10):3207-.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bona R, Wallace D, Hickey A, Wajcs S</AU>
<TI>Thrombin generation and activity are increased in patients with cancer receiving sodium warfarin as secondary prophylaxis against venous thrombosis</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>10</NO>
<PG>3207</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Browse-1974" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Browse 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Browse N. Blood and neoplastic diseases. Thrombosis: treatment and prophylaxis. British Medical Journal. 1974 Oct 12;4(5936):96-9.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:56 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browse N</AU>
<TI>Blood and neoplastic diseases. Thrombosis: treatment and prophylaxis</TI>
<SO>BMJ</SO>
<YR>1974</YR>
<VL>4</VL>
<NO>5936</NO>
<PG>96-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgos-1999" NAME="Burgos 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Burgos A, Alcaide A, Alcoba C, Azcona J, Garrido J, Lorente C, et al. Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. Lymphology. 1999 Mar;32(1):3-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgos A, Alcaide A, Alcoba C, Azcona J, Garrido J, Lorente C et al</AU>
<TI>Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer</TI>
<SO>Lymphology</SO>
<YR>1999</YR>
<VL>32</VL>
<NO>1</NO>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke_x002d_Pearson-1983" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Clarke-Pearson 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Clarke Pearson D, Synan I, Creasman W. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. American Journal of Obstetrics &amp;amp; Gynecology. 1983;147(4):369-75.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke-Pearson D, Synan I, Creasman W</AU>
<TI>Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>1983</YR>
<VL>147</VL>
<NO>4</NO>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clenney-2003" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Clenney 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Clenney TL, Viera AJ. Heparin prevents recurrent VTE in cancer patients. Journal of Family Practice. 2003;52(11):843-4.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clenney TL, Viera AJ</AU>
<TI>Heparin prevents recurrent VTE in cancer patients</TI>
<SO>Journal of Family Practice</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>11</NO>
<PG>843-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Das-1996" MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NAME="Das 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery 1996;20(5):521-6; discussion 6-7.&lt;/p&gt;" NOTES_MODIFIED="2011-02-17 21:28:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV</AU>
<TI>Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial</TI>
<SO>World Journal of Surgery</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>5</NO>
<PG>521-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daskalopoulos-2005" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Daskalopoulos 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (Tinzaparin): A prospective randomized trial. European Journal of Vascular and Endovascular Surgery 2005;29(6):638-50.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D et al</AU>
<TI>Long-term treatment of deep venous thrombosis with a low molecular weight heparin (Tinzaparin): a prospective randomized trial</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>6</NO>
<PG>638-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-2005" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Eriksson 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran VICOTR, WE NEED THE REFERENCED (THRIVE III). Thrombosis &amp;amp; Haemostasis. 2005;94(3):522-7.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson H, Lundstrom T, Wahlander K, Clason SB, Schulman S</AU>
<TI>Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>3</NO>
<PG>522-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farred-2004" NAME="Farred 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Farred J, al e. Multifactorial etiology of cancer associated venous thrombosis: results from profiling of cancer patients recruited in a study of the secondary prevention of thrombosis with low molecular weight heparin. 2004 ASCO Annual Meeting Proceedings. 2004.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Farred J</AU>
<TI>Multifactorial etiology of cancer associated venous thrombosis: results from profiling of cancer patients recruited in a study of the secondary prevention of thrombosis with low molecular weight heparin</TI>
<SO>2004 ASCO Annual Meeting Proceedings</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferretti-2005" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Ferretti 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Ferretti G, Bria E, Carlini P, Felici A, Giannarelli D, Ciccarese M, et al. Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality. Journal Of Clinical Oncology. 2005 Jun 1;23(16):765S-S.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti G, Bria E, Carlini P, Felici A, Giannarelli D, Ciccarese M et al</AU>
<TI>Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>16</NO>
<PG>765S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferretti-2006" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Ferretti 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti G</AU>
<TI>Does low-molecular-weight heparin influence cancer-related mortality?</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1604-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiessinger-2005" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Fiessinger 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - A randomized trial. Jama-Journal of the American Medical Association 2005;293(6):681-9.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H et al</AU>
<TI>Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - a randomized trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>6</NO>
<PG>681-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez_x002d_Fajardo-1999" MODIFIED="2013-10-25 10:28:01 +0100" MODIFIED_BY="Gail Quinn" NAME="Gonzalez-Fajardo 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery. 1999 Aug;30(2):283-92.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I et al</AU>
<TI>Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>2</NO>
<PG>283-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-1996" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Hull 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Hull RD, Pineo GF, Brant RF. Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clinical And Applied Thrombosis-Hemostasis. 1996;2:S4-S11.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant RF</AU>
<TI>Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis</TI>
<SO>Clinical and Applied Thrombosis-Hemostasis</SO>
<YR>1996</YR>
<VL>2</VL>
<PG>S4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2000" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Hull 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Hull RD, Pineo GF, Brant RF. A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin. 2000;37(1 SUPPL. 1):123-32.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant RF</AU>
<TI>A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis</TI>
<SO>Intensivmedizin und Notfallmedizin</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>1 Suppl 1</NO>
<PG>123-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2007" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Hull 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R et al</AU>
<TI>Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms</TI>
<SO>American Journal of Medicine</SO>
<YR>2007</YR>
<VL>120</VL>
<PG>72-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2009" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Hull 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S et al</AU>
<TI>Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome</TI>
<SO>American Journal of Medicine</SO>
<YR>2009</YR>
<VL>122</VL>
<PG>762-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hyers-2005" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Hyers 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Hyers TM. Long-term anticoagulation prophylaxis following acute thromboembolism. Disease A Month. 2005;51(2-3):158-65.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hyers TM</AU>
<TI>Long-term anticoagulation prophylaxis following acute thromboembolism</TI>
<SO>Disease-a-Month</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>2-3</NO>
<PG>158-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iorio-2003" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Iorio 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. Journal of Thrombosis &amp;amp; Haemostasis. 2003 Sep;1(9):1906-13.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iorio A, Guercini F, Pini M</AU>
<TI>Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>9</NO>
<PG>1906-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-2003" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Kakkar 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P</AU>
<TI>Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis - Stuttgart</SO>
<YR>2003</YR>
<VL>89</VL>
<NO>4</NO>
<PG>674-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-2005" NAME="King 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;King KM, Wong C, Nutescu E, Shord SS. Warfarin dose requirements in cancer and non-cancer. Pharmacotherapy. 2005 Mar;25(3):468-.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King KM, Wong C, Nutescu E, Shord SS</AU>
<TI>Warfarin dose requirements in cancer and non-cancer</TI>
<SO>Pharmacotherapy</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>468</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kovacs-2005" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Kovacs 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Kovacs MJ, Levine MN, Keeney M, Mackinnon KM, Lee AY. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thrombosis &amp;amp; Haemostasis. 2005 Jun;93(6):1185-8.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kovacs MJ, Levine MN, Keeney M, Mackinnon KM, Lee AY</AU>
<TI>Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2005</YR>
<VL>93</VL>
<NO>6</NO>
<PG>1185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kucher-2005" MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NAME="Kucher 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kucher N, Quiroz R, McKean S, Sasahara AA, Goldhaber SZ, Kucher N, et al. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine 2005;10(4):251-6.&lt;/p&gt;" NOTES_MODIFIED="2011-02-17 21:28:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kucher N, Quiroz R, McKean S, Sasahara AA, Goldhaber SZ, Kucher N et al</AU>
<TI>Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism</TI>
<SO>Vascular Medicine</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>4</NO>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee A, Levine M</AU>
<TI>Treatment of venous thromboembolism in cancer patients</TI>
<SO>Cancer Control</SO>
<YR>2005</YR>
<VL>12 Suppl 1</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2006" NAME="Lee 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AYY</AU>
<TI>Dalteparin sodium in the management of thromboembolic disorder</TI>
<SO>Therapy</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>4</NO>
<PG>461-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1995" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Levine 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thrombosis &amp;amp; Haemostasis. 1995 Aug;74(2):606-11.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J et al</AU>
<TI>Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1995</YR>
<VL>74</VL>
<NO>2</NO>
<PG>606-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2003" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Levine 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine MN, Lee AY, Kakkar AK</AU>
<TI>From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>7</NO>
<PG>1456-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopaciuk-1999" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Lopaciuk 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis &amp;amp; Haemostasis 1999;81(1):26-31.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S et al</AU>
<TI>Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-1999" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Loprinzi 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.[see comment]. New England Journal of Medicine. 1999 Feb 4;340(5):346-50.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P et al</AU>
<TI>Lack of effect of coumarin in women with lymphedema after treatment for breast cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>5</NO>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massicotte-2003" MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NAME="Massicotte 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-17 21:28:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research. 2003 Jan 25;109(2-3):85-92.&lt;/p&gt;" NOTES_MODIFIED="2011-02-17 21:28:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B et al</AU>
<TI>An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial</TI>
<SO>Thrombosis Research</SO>
<YR>2003</YR>
<VL>109</VL>
<NO>2-3</NO>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCan-2000" NAME="McCan 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;McCan J. New oral anticoagulant and cancer drug believed to be firsts. Drug Topics. 2000;144(1).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCan J</AU>
<TI>New oral anticoagulant and cancer drug believed to be firsts</TI>
<SO>Drug Topics</SO>
<YR>2000</YR>
<VL>144</VL>
<NO>1</NO>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olin-1987" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Olin 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Archives of Internal Medicine. 1987 Dec;147(12):2177-9.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW</AU>
<TI>Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>12</NO>
<PG>2177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palareti-2000" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Palareti 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A, et al. A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thrombosis &amp;amp; Haemostasis. 2000;84(5):805-10.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:56 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A et al</AU>
<TI>A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>5</NO>
<PG>805-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Partsch-2001" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Partsch 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, compression and walking exercises. Anales de Cirugia Cardiaca y Cirugia Vascular. 2001;7(4):322-4.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Partsch H</AU>
<TI>Therapy of deep vein thrombosis with low molecular weight heparin, compression and walking exercises</TI>
<SO>Anales de Cirugia Cardiaca y Cirugia Vascular</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>4</NO>
<PG>322-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-P_x00e9_rez_x002d_de_x002d_Llano-2010" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Pérez-de-Llano 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pérez-de-Llano LA, Leiro-Fernández V, Golpe R, Núñez-Delgado JM, Palacios-Bartolomé A, Méndez-Marote L et al</AU>
<TI>Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study</TI>
<SO>Blood Coagulation Fibrinolysis</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>8</NO>
<PG>744-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinede--2001" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Pinede  2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001 May 22;103(20):2453-60.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I et al</AU>
<TI>Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>20</NO>
<PG>2453-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pini-1994" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Pini 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis &amp;amp; Haemostasis 1994;72(2):191-7.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T et al</AU>
<TI>Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>2</NO>
<PG>191-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2006" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Schulman 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P et al</AU>
<TI>Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>4</NO>
<PG>734-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-2005" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Schwartz 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Schwartz RN. Considerations and challenges with existing treatments for thrombosis in cancer patients. American Journal Of Health-System Pharmacy. 2005 Nov 15;62:S7-S9.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RN</AU>
<TI>Considerations and challenges with existing treatments for thrombosis in cancer patients</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2005</YR>
<VL>62</VL>
<PG>S7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-2003" NAME="Scott 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Scott I. In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage. Evidence Based Medicine. 2003;8(3):85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott I</AU>
<TI>In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage</TI>
<SO>Evidence Based Medicine</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>3</NO>
<PG>85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shattil-1984" NAME="Shattil 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Shattil SJ. Diagnosis and treatment of recurrent venous thromboembolism. Medical Clinics of North America. 1984;68(3):577-600.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shattil SJ</AU>
<TI>Diagnosis and treatment of recurrent venous thromboembolism</TI>
<SO>Medical Clinics of North America</SO>
<YR>1984</YR>
<VL>68</VL>
<NO>3</NO>
<PG>577-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siragusa-2010" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Siragusa 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siragusa S, Malato A, Mascheroni D, Ageno W, Bucherini E, Spadaro P et al</AU>
<TI>The optimal duration of anticoagulant therapy in patients with cancer-related deep vein thrombosis: the advantage of using residual vein thrombosis (the Cancer-DACUS Study)</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>87-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solymoss-1999" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Solymoss 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Solymoss S. Optimizing the duration of anticoagulation therapy for venous thrombosis. Canadian Medical Association Journal. 1999;160(9):1317-8.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solymoss S</AU>
<TI>Optimizing the duration of anticoagulation therapy for venous thrombosis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>160</VL>
<NO>9</NO>
<PG>1317-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stine-2004" NAME="Stine 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Stine K, Saylors R, Saccente S, Becton D. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Blood. 2004 Nov 16;104(11):102B-B.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stine K, Saylors R, Saccente S, Becton D</AU>
<TI>Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<NO>11</NO>
<PG>102B</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streiff-2006" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Streiff 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streiff MB</AU>
<TI>Long-term therapy of venous thromboembolism in cancer patients</TI>
<SO>Journal of the National Comprehensive Cancer Network</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>9</NO>
<PG>903-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suarez-Alvarez-2003" MODIFIED="2014-05-23 14:23:53 +0100" MODIFIED_BY="Anne Lawson" NAME="Suarez Alvarez 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Suarez Alvarez CG, Garcia Canete J, Herrero Mendoza MD, Bellver Alvarez TM, Arboiro Pinel R. [Treatment of deep vein thrombosis with low molecular weight heparins at home]. An Med Interna. 2003 Mar;20(3):134-6.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suarez Alvarez CG, Garcia Canete J, Herrero Mendoza MD, Bellver Alvarez TM, Arboiro Pinel R</AU>
<TI>Treatment of deep vein thrombosis with low molecular weight heparins at home</TI>
<SO>Anales de Medicina Interna</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>3</NO>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taliani-2003" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Taliani 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. Journal Of Thrombosis And Haemostasis. 2003 Aug;1(8):1730-3.&lt;/p&gt;" NOTES_MODIFIED="2014-06-04 10:23:55 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M et al</AU>
<TI>Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>8</NO>
<PG>1730-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tedoldi-1993" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Tedoldi 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Tedoldi A. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials Metanalysis. 1993;28(215-223).&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tedoldi A</AU>
<TI>Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis</TI>
<SO>Clinical Trials and Meta-Analysis</SO>
<YR>1993</YR>
<VL>28</VL>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veiga-2000" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Veiga 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veiga F, Escriba A, Maluenda MP, Lopez Rubio M, Margalet I, Lezana A et al</AU>
<TI>Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>4</NO>
<PG>559-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vucic-2002" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Vucic 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Vucic N, Ostojic R, Svircic T. Treatment of deep vein thrombosis with oral anticoagulants ill patients with malignancy: Prospective cohort study. Croatian Medical Journal. 2002 Jun;43(3):296-300.&lt;/p&gt;" NOTES_MODIFIED="2011-04-04 10:25:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vucic N, Ostojic R, Svircic T</AU>
<TI>Treatment of deep vein thrombosis with oral anticoagulants ill patients with malignancy: prospective cohort study</TI>
<SO>Croatian Medical Journal</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>3</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Kamphuisen-2010_x0028_Longheva_x0029_" MODIFIED="2013-11-05 11:44:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kamphuisen 2010(Longheva)" YEAR="2010">
<IDENTIFIERS MODIFIED="2013-11-05 11:44:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-05 11:44:53 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01164046"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2013" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Lee 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G et al</AU>
<TI>CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. PROTOCOL</TI>
<SO>BMC Cancer</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>1</NO>
<PG>284</PG>
<IDENTIFIERS MODIFIED="2013-10-28 09:38:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-28 09:38:18 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01130025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G et al</AU>
<TI>CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>Suppl</VL>
<PG>TPS9149</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-28 09:38:38 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-28 09:38:38 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01130025"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noble-2013-_x0028_ALICAT_x0029_" MODIFIED="2014-03-21 10:54:47 +0000" MODIFIED_BY="[Empty name]" NAME="Noble 2013 (ALICAT)" YEAR="2013">
<IDENTIFIERS MODIFIED="2014-03-21 10:54:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-21 10:54:47 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01817257"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<REFERENCE ID="REF-Akl-2011" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Akl 2011" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P et al</AU>
<TI>Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-04-26 12:29:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-26 12:29:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006650.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2013" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Akl 2013" TYPE="JOURNAL_ARTICLE">
<AU>Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M et al</AU>
<TI>Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e57132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-2008" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Ansell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G</AU>
<TI>Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)</TI>
<SO>Chest</SO>
<YR>2008</YR>
<VL>133</VL>
<NO>Suppl 6</NO>
<PG>160S-98S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conti-2003" NAME="Conti 2003" TYPE="JOURNAL_ARTICLE">
<AU>Conti S, Guercini F, Iorio A</AU>
<TI>Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months</TI>
<SO>Pathophysiology of Haemostasis &amp; Thrombosis</SO>
<YR>2003</YR>
<VL>33</VL>
<NO>4</NO>
<PG>197-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebrahim-2013" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="Ebrahim 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D et al</AU>
<TI>Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1014-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallus-1997" MODIFIED="2011-05-03 14:08:12 +0100" MODIFIED_BY="Gail Quinn" NAME="Gallus 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gallus AS</AU>
<TI>Prevention of post-operative deep leg vein thrombosis in patients with cancer</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>1</NO>
<PG>126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-2002" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Haynes 2002" TYPE="JOURNAL_ARTICLE">
<AU>Haynes RB, Devereaux PJ, Guyatt GH</AU>
<TI>Clinical expertise in the era of evidence-based medicine and patient choice</TI>
<SO>Vox Sanguinis</SO>
<YR>2002</YR>
<VL>83 Suppl 1</VL>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heit-2000" NAME="Heit 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd</AU>
<TI>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>6</NO>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins J</AU>
<TI>Publication bias and funnel plots</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6</SO>
<YR>2006</YR>
<PG>151-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1993" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Hirsh 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J</AU>
<TI>Low molecular weight heparin</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>1</NO>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutten-2000" NAME="Hutten 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR</AU>
<TI>Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>17</NO>
<PG>3078-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kakkar-1970" MODIFIED="2011-05-03 14:07:54 +0100" MODIFIED_BY="Gail Quinn" NAME="Kakkar 1970" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB</AU>
<TI>Deep vein thrombosis of the leg. Is there a "high risk" group?</TI>
<SO>American Journal of Surgery</SO>
<YR>1970</YR>
<VL>120</VL>
<NO>4</NO>
<PG>527-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levitan-1999" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NAME="Levitan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R et al</AU>
<TI>Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data</TI>
<SO>Medicine</SO>
<YR>1999</YR>
<VL>78</VL>
<NO>5</NO>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT00067093" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NAME="NCT00067093" TYPE="OTHER">
<AU>NCT00067093</AU>
<TI>Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)</TI>
<SO>clinicaltrials.gov/ct/show/NCT00067093</SO>
<YR>(accessed 22 May 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2011-05-03 14:07:49 +0100" MODIFIED_BY="Gail Quinn" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-10-25 09:55:12 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-2000" MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Sorensen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA</AU>
<TI>Prognosis of cancers associated with venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>25</NO>
<PG>1846-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijden-2007" MODIFIED="2011-05-03 14:08:24 +0100" MODIFIED_BY="Gail Quinn" NAME="van der Heijden 2007" TYPE="COCHRANE_REVIEW">
<AU>van der Heijden JF, Hutten BA, Büller HR, Prins MH</AU>
<TI>Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-04-03 12:09:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-03 12:09:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002001"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Cesarone-2003">
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>199 patients with cancer patients with DVT</P>
<P>17 drop-outs, 182 patients completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: enoxaparin 100 IU/kg twice daily x 3 months</P>
<P>Control: coumadin (target INR 3) x 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 3 months</P>
<UL>
<LI>Mortality</LI>
<LI>Major bleeding</LI>
<LI>Recurrent DVT or PE but no data available</LI>
</UL>
<P>Diagnostic tests of DVT: ultrasound</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Deitcher-2006">
<CHAR_METHODS MODIFIED="2014-04-22 10:14:52 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized clinical trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>102 patients with active cancer with DVT, PE, or both; </P>
<P>85% Caucasian, </P>
<P>mean age 64 years, 46% male, previous VTE 8.7%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: enoxaparin 1 mg/kg twice daily x 5 days followed by 1.0-1.5 mg/kg daily x 175 days (group 1a); enoxaparin 1.5 mg/kg daily x 175 days (group 1b)</P>
<P>Control: enoxaparin 1 mg/kg twice daily x 5 days followed by warfarin (target INR 2-3) for a total of 180 days</P>
<P>Co-intervention: chemotherapy, radiation therapy, or both (not better specified)</P>
<P>Discontinued treatment: 52 of 102 patients overall</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 1 year</P>
<UL>
<LI>Mortality</LI>
<LI>Symptomatic recurrent VTE</LI>
<LI>Major bleeding</LI>
<LI>Minor bleeding</LI>
</UL>
<P>No scheduled radiologic surveillance for VTE was conducted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: Aventis Pharmaceutical</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hull-2006">
<CHAR_METHODS MODIFIED="2014-04-22 10:14:53 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>200 patients with cancer (solid or hematologic) with proximal DVT with or without PE</P>
<P>Minimum age 18 years; minimum life expectancy 3 months, </P>
<P>50% male, </P>
<P>19% had previous VTE </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Interventions: tinzaparin 175 antiXa/kg SC daily for 12 weeks</P>
<P>Control: UFH either 5000 U or 80 U/kg for 5 days followed by VKA (target INR 2-3) for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 12 months</P>
<UL>
<LI>Recurrent VTE evaluated at 3 and 12 months</LI>
<LI>Bleeding (major and minor) evaluated at 3 months</LI>
<LI>Mortality at 3 and 12 months</LI>
</UL>
<P>Diagnostic test for recurrent VTE: venography or compression ultrasonography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Funding: Canadian Institute for Health Research, industry grant, Leo Pharmaceutical, Pharmion Pharmaceutical, and DuPont Pharmaceutical<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lee-2003">
<CHAR_METHODS MODIFIED="2014-04-22 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>676 patients with active cancer and with DVT, PE, or both; ECOG 1 or 2</P>
<P>Mean age 63 years, 49% male,11% history of DVT/PE<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: dalteparin 200 IU/kg daily x 1 month followed by 150 IU/kg daily x 5 months</P>
<P>Control: dalteparin 200 IU/kg daily x 5-7 days followed by warfarin or acenocoumarol (target INR 2-3) x 6 months; 46% of time on target</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 6 months</P>
<UL>
<LI>Symptomatic recurrent DVT and PE</LI>
<LI>Clinically overt bleeding (both major bleeding and any bleeding)</LI>
<LI>Mortality</LI>
</UL>
<P>Diagnostic tests for DVT: ultrasonography, venography</P>
<P>Diagnostic tests for PE: lung scan, angiography, autopsy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-20 20:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Pharmacia<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<CHAR_METHODS MODIFIED="2014-04-22 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>35 patients with known malignancy; treated for symptomatic DVT of the lower limbs</P>
<P>Minimum age 18 years, mean age 65.7 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: nadroparin 1.025 AXa IU/10 kg twice daily for 3 days then randomized to nadroparin 1.025 antiXa IU/10 kg twice daily</P>
<P>Control: nadroparin 1.025 AXa IU/10 kg twice daily for 3 days then randomized to acenocoumarol (target INR 2-3) for 3-6 months. After the 3rd month, nadroparin was switched to once daily. 68% of INR values were on target</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Mortality DVT, PE, asymptomatic VTE, major bleeding, venous insufficiency</P>
<P>Duplex scan exam performed during routine vascular clinic visits at 1, 3, 6, and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Meyer-2002">
<CHAR_METHODS MODIFIED="2014-04-22 10:14:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>146 patients with cancer (solid or hematologic; active or in remission but on treatment); with PE, DVT, or both</P>
<P>Minimum age 18 years; minimum life expectancy 3 months, </P>
<P>mean age 65.5 years, 45% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: enoxaparin 1.5 mg/kg daily x 3 month</P>
<P>Control: enoxaparin 1.5 mg/kg daily x 4 days followed by warfarin (target INR 2-3) x 3 months; 41% of time on target</P>
<P>The continuation and nature of anticoagulant treatment after 3 months were left to the attending physician</P>
<P>Co-intervention: not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 3 and 6 months</P>
<UL>
<LI>Asymptomatic VTE</LI>
<LI>Symptomatic and objectively confirmed recurrent VTE</LI>
<LI>Major bleeding</LI>
<LI>Minor bleeding</LI>
<LI>Thrombocytopenia</LI>
</UL>
<P>Screening tests for VTE: radiologic surveillance</P>
<P>Diagnostic tests for DVT: venography or compression ultrasonography</P>
<P>Diagnostic tests for PE: pulmonary angiography or ventilation perfusion scanning<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: Aventis, Assistance Publique, Hospitaux de Paris</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Romera-2009">
<CHAR_METHODS MODIFIED="2011-04-03 11:23:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>69 patients with cancer (study subgroup) and symptomatic proximal DVT</P>
<P>Minimum age 18 years, mean age 61 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: tinzaparin SC in a fixed dose of 175 IU anti-Xa per kg once daily for 6 months</P>
<P>Control: acenocoumarol 3 mg orally, which was subsequently adjusted to achieve an INR of 2-3</P>
<P>All patients received tinzaparin SC in a fixed dose of 175 IU anti-Xa per kg once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>VTE (no data available for other outcomes in patients with cancer)</P>
<P>Scheduled radiologic surveillance for VTE was conducted at 1, 6, and 12 months after entry</P>
<P>Screening testing for DVT: none</P>
<P>Diagnostic testing for DVT: duplex ultrasonography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">
<P>Funding: Hospital Universitari de Bellvitge, LEO Pharma<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2003">
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Double-blind randomized trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>66 patients with active cancer in the previous 5 years (study subgroup); treated for DVT or PE for 6 months without recurrence</P>
<P>Minimum age 18 years, mean age 57 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: initial anticoagulant treatment for 6 months; extended treatment with ximelagatran 24 mg twice daily x 18 months</P>
<P>Control: initial anticoagulant treatment for 6 months; placebo x 18 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 18 months</P>
<UL>
<LI>Mortality</LI>
<LI>Asymptomatic recurrent VTE (DVT and PE)</LI>
<LI>Major bleeding</LI>
<LI>Minor bleeding (no data available for patients with cancer patients subgroup)</LI>
</UL>
<P>No scheduled radiologic surveillance for VTE was conducted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: AstraZeneca</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2009">
<CHAR_METHODS MODIFIED="2011-04-04 10:25:04 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>121 patients with cancer (study subgroup) with DVT, PE, or both</P>
<P>Minimum age 18 years; mean age 60.5 years; 94.8% white people, 2.6% black people, 2.6% Asian people</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: dabigatran 150 mg twice daily for 6 months</P>
<P>Control: warfarin adjusted to achieve an INR of 2-3 for 6 months</P>
<P>All patients were initially given parenteral anticoagulant therapy for a median of 9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Mortality, symptomatic VTE, major bleeding, and minor bleeding at 6 months</P>
<P>No scheduled radiologic surveillance for VTE was conducted (no data available in the paper, )</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-14 15:02:22 +0000" MODIFIED_BY="[Empty name]">
<P>Funding: Boehringer Ingelheim Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-van-Doormaal-2010">
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Post hoc analysis in the subgroup of patients with cancer included in the Van Gogh DVT clinical trial (<LINK REF="REF-NCT00067093" TYPE="REFERENCE">NCT00067093</LINK>)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>421 patients with a history or current cancer having acute symptomatic and objectively confirmed DVT involving the popliteal, femoral, iliac veins, or the trifurcation of the calf veins, without symptomatic PE</P>
<P>67% with active disease at entry, 53% male, mean age 67 years</P>
<P>Quote: "no detailed information on cancer type and stage or co-medication was collected"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: idraparinux 2.5 mg SC once-weekly x 3 or 6 months according to the decision of the treating physician</P>
<P>Control: standard treatment: tinzaparin, enoxaparin, or intravenous heparin adjusted for the activated partial thromboplastin time ratio (ratio 1.5-2.5), followed by warfarin or acenocoumarol (INR 2-3), which was started within 24 hours after randomization</P>
<P>Co-intervention: not reported</P>
<P>Quote: "A total of 8% of all patients were randomised in the 3-month arm, and 92% in the 6-month treatment arm"</P>
<P>Quote: "The duration of treatment was similar with a median of 183 days in both groups"</P>
<P>75% of participants completed the study medication</P>
<P>Quote: "Of idraparinux recipients 48 patients (22%) stopped the study medication before the end of the study compared to 56 (28%) patients in the standard treatment arm"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 6-month treatment period plus additional 3-month follow-up period (median 183 days in both groups)</P>
<UL>
<LI>Symptomatic objectively confirmed recurrent VTE: DVT (follow-up at 3 and 6 months ), non-fatal or fatal PE (follow-up at 6 and 9 months)</LI>
<LI>Clinically relevant major bleeding (follow-up at 3 and 6 months)</LI>
<LI>Clinically relevant non-major bleeding (follow-up at 3 and 6 months)</LI>
<LI>All-cause mortality (follow-up at 6 and 9 months)</LI>
</UL>
<P>Screening testing for DVT/PE: none<BR/>Diagnostic testing for DVT/PE: none reported in this manuscript, but available from Buller HR, <I>New England Journal of Medicine</I> 2007;357:1094-104. For diagnosis of recurrent PE: spiral computed tomography, pulmonary angiography. For diagnosis of recurrent DVT: ultrasonography, venography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Quote: "This post-hoc analysis is under-powered to adequately test the hypothesis of equivalence and should be considered as hypothesis generating"</P>
<P>Quote: "The data were gathered and maintained by the sponsor"</P>
<P>Note: Sanofi-Aventis France is idraparinux manufacturer</P>
<P>Quote: "The original trial was sponsored by Sanofi-Aventis. Their biostatisticians extracted the data of the present study"</P>
<P>Comment: probably not blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DVT: deep venous thrombosis; ECOG: Eastern Co-operative Oncology Group; INR: international normalized ratio; IU: international units; PE: pulmonary embolism; SC: subcutaneous; U: unit; UFH: unfractionated heparin; VKA: vitamin K antagonist; VTE: venous thromboembolism.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Altschuler-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT (no control group)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andrea-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Astermark-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beckman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:11 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bona-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT (no control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Browse-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burgos-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant outcome<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clarke_x002d_Pearson-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clenney-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Das-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:14 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daskalopoulos-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:15 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Eriksson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Too few patients with cancer (1 in LMWH group)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Farred-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferretti-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferretti-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of another study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiessinger-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:18 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez_x002d_Fajardo-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:20 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hull-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Protocol<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hull-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Protocol<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-25 11:21:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hull-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-25 11:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-25 11:21:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hull-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-25 11:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hyers-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iorio-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Kakkar-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>No patients with cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-King-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kovacs-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kucher-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:22 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:24 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopaciuk-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:26 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loprinzi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No relevant outcome <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massicotte-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:29 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olin-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Palareti-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Partsch-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Pinede--2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>No patients with cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pini-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:31 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-25 11:22:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-P_x00e9_rez_x002d_de_x002d_Llano-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-25 11:22:18 +0100" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>No patients with cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwartz-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scott-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shattil-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-25 11:35:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siragusa-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-25 11:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>Not intervention of interest: different duration of interventional drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Solymoss-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stine-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Streiff-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Suarez-Alvarez-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Not an RCT (no control group)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taliani-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Tedoldi-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>No patients with cancer in study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-17 21:29:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veiga-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-17 21:29:35 +0000" MODIFIED_BY="[Empty name]">
<P>Study included patients with cancer as a subgroup for which outcome data were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vucic-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>LMWH: low molecular weight heparin; RCT: randomized controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Kamphuisen-2010_x0028_Longheva_x0029_">
<CHAR_STUDY_NAME MODIFIED="2014-04-22 10:15:02 +0100" MODIFIED_BY="[Empty name]">
<P>Longheva</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Multicenter, multinational, randomized, open-label trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Participants with malignancy (all types, solid and hematologic) who have received 6-12 months of anticoagulation for VTE and have an indication for continuing anticoagulation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: weight-adjusted scheme of LMWH for 6 additional months, 65-75% of full therapeutic dose</P>
<P>Control: vitamin K antagonists for 6 additional months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 10:15:02 +0100" MODIFIED_BY="[Empty name]">
<P>Symptomatic recurrent VTE (DVT and PE)</P>
<P>All clinically relevant bleeding (i.e. major bleeding and other clinically relevant non-major bleeding) </P>
<P>All-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>August 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Prof. Pieter W. Kamphuisen, telephone: 0031503612943, email: <A HREF="mailto:p.w.kamphuisen%40umcg.nl?subject=NCT01164046,%20EudraCT%20nr:%202009-015336-15,%20Long-term%20Treatment%20for%20Cancer%20Patients%20With%20Deep%20Venous%20Thrombosis%20or%20Pulmonary%20Embolism">p.w.kamphuisen@umcg.n</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lee-2013">
<CHAR_STUDY_NAME MODIFIED="2014-04-21 13:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. PROTOCOL</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Phase III, multinational, concealed, randomized, active-controlled, open-label trial with blinded adjudication</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Adults diagnosed with active cancer and a histologically or cytologically confirmed solid tumor or hematologic malignancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: tinzaparin 175 IU/kg once daily for 180 days (almost 6 months)</P>
<P>Control: warfarin once daily (target INR 2.0-3.0) overlapping with initial tinzaparin 175 IU/kg once daily (5-10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Duration of follow-up: 1 month after last day of treatment (at 6 months)</P>
<UL>
<LI>Symptomatic DVT</LI>
<LI>Symptomatic non-fatal PE</LI>
<LI>Fatal PE</LI>
<LI>Incidental proximal DVT (popliteal vein or higher)</LI>
<LI>Incidental proximal PE (segmental arteries or larger)</LI>
<LI>Major bleeding</LI>
<LI>Clinically relevant nonmajor bleeding</LI>
<LI>All-cause mortality</LI>
<LI>Heparin-induced thrombocytopenia</LI>
<LI>Risk factors for recurrent VTE</LI>
<LI>Post-thrombotic syndrome</LI>
<LI>Health-related quality of life</LI>
<LI>Healthcare resource utilization</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-29 08:21:31 +0000" MODIFIED_BY="[Empty name]">
<P>August 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Email: Agnes.Lee@phsa.ca</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-29 08:20:39 +0000" MODIFIED_BY="[Empty name]">
<P>NCT01130025</P>
<P>Funding: LEO Pharma</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Noble-2013-_x0028_ALICAT_x0029_">
<CHAR_STUDY_NAME MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>ALICAT</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Randomized, open-label, multicenter, mixed methods feasibility study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Intervention: LMWH at treatment dose according to body weight for further 6 months</P>
<P>Control: no LMWH</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Participants aged &#8805; 16 years with locally advanced or metastatic cancer receiving LMWH for treatment of catheter-associated thrombosis for 5 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>Quality of life</P>
<P>Toxicities, including bleeding events and VTEs</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>March 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<P>Dr. Joanna D Smith, telephone: +44 (0)2920 687463, email: <A HREF="mailto:sealjd%40cf.ac.uk?subject=NCT01817257,%20SPON1037-11,%20Anticoagulation%20Length%20in%20Cancer%20Associated%20Thrombosis">sealjd@cf.ac.uk</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-22 10:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Cardiff University</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>DVT: deep venous thrombosis; LMWH: low molecular weight heparin; PE: pulmonary embolism; VTE: venous thromboembolism.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Quote: "randomised outpatient trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "patients were randomly allocated"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "a computer-derived randomised treatment schedule was used; within the each stratum, the randomised schedule was balanced in blocks of 2 and 4"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "randomizations was stratified according to the clinical center and centralized at the coordinating and methods center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "patients were allocated at random on third day to receive a LMWH or an OA [oral anticoagulant]"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "Treatment allocation was balanced at each center in blocks of 4"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "patients were randomised to either LMWH group SQ [subcutaneous] or LMWH followed by acenocoumarol"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "use of a computer-generated randomizations list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "we used a computer generated randomisation scheme with variable block size stratified according to the presentation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Quote: "After giving written informed consent, patients were randomly assigned to receive either idraparinux or standard therapy with the use of a computerized voice-response system" (from Buller HR, <I>New England Journal of Medicine</I> 2007;357:1094-104)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:12:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "This pilot feasibility study was conducted as a randomised, open label&#8230;.trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "multicenter, open-label randomised design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "the open label design could be a potential source of bias"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "randomisation was performed using pre sealed treatment boxes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "A randomised, open-label trial"</P>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "the treatment group assignment was concealed from all the investigators and their staff at the coordinating center and the clinical centers and from clinical monitors"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "the treatment group assignment were concealed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Quote: "After giving written informed consent, patients were randomly assigned to receive either idraparinux or standard therapy with the use of a computerized voice-response system" (from Buller HR, <I>New England Journal of Medicine</I> 2007;357:1094-104)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-05-23 14:11:52 +0100" MODIFIED_BY="Anne Lawson" NO="7">
<NAME/>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="8">
<NAME>Blinding of patients?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated intervention by the patients adequately?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "open label"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "open label clinical trial"</P>
<P>Quote: "A double-blind design was not feasible due to geographic location of many of the centres and necessarily large number of primary care physicians providing anticoagulant monitoring"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "we performed a multicenter, randomised, open label, clinical trial"</P>
<P>Quote: "we believed that a double blind design would not logistically feasible or safe in patient with cancer"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "in view of the nature of the treatments, it was not possible to use a double design for the study"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "this study was a multicenter, open label, randomised trial"</P>
<P>Comment: probably no<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "we performed a randomised open label clinical trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "multicenter, double blind, placebo-controlled parallel group study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "double blind, double dummy randomised trial"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-13 09:15:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Open-label study</P>
<P>Comment: probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="9">
<NAME>Blinding of the providers?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "open label"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "open label clinical trial"</P>
<P>Quote: "A double-blind design was not feasible due to geographic location of many of the centres and necessarily large number of primary care physicians providing anticoagulant monitoring"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "we performed a multicenter, randomised, open label, clinical trial"</P>
<P>Quote: "we believed that a double blind design would not logistically feasible or safe in patient with cancer"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "in view of the nature of the treatments, it was not possible to use a double design for the study"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "this study was a multicenter, open label, randomised trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "we performed a randomised open label clinical trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "multicenter, double blind, placebo-controlled parallel group study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "double blind, double dummy randomised trial"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-13 09:15:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Open-label study</P>
<P>Comment: probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="10">
<NAME>Blinding of the data collectors?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "open label"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "open label clinical trial"</P>
<P>Quote: "A double-blind design was not feasible due to geographic location of many of the centres and necessarily large number of primary care physicians providing anticoagulant monitoring"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "we performed a multicenter, randomised, open label, clinical trial"</P>
<P>Quote: "we believed that a double blind design would not logistically feasible or safe in patient with cancer"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "in view of the nature of the treatments, it was not possible to use a double design for the study"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "this study was a multicenter, open label, randomised trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "All objective diagnostic tests were interpreted by specialists who were not involved in the study"</P>
<P>Quote: "the ultrasonic evaluations were performed blindly"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "multicenter, double blind, placebo-controlled parallel group study"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "double blind, double dummy randomised trial"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-13 09:15:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Open-label study</P>
<P>Comment: probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="11">
<NAME>Blinding of data analysis?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "open label"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "open label clinical trial"</P>
<P>Quote: "A double-blind design was not feasible"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "a blinded reassessment of the sample size was specified in the protocol"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "in view of the nature of the treatments, it was not possible to use a double design for the study"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "this study was a multicenter, open label, randomised trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "we performed a randomised open label clinical trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "multicenter, double blind, placebo-controlled parallel group study"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "double blind, double dummy randomised trial"</P>
<P>Comment: probably no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-13 09:15:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Open-label study</P>
<P>Comment: probably not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="12">
<NAME>Blinding of the outcome adjudicators?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "open label"</P>
<P>Comment: probably not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Quote: "Adjudication was made by 2 committee members not involved in the patient&#8217;s care, and disputes were resolved independently by a third. Members of the committee were unaware of the patients' treatment assignments"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "all suspected events were reviewed by a central adjudication committee whose members were unaware of the patient's treatment assignments"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Quote: "the final allocation of all potential outcome events, including deaths, was made by an independent panel of physicians"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "all potential outcome events were assessed by an independent adjudication committee whose members were unaware of the treatment assignment"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "All objective diagnostic tests were interpreted by specialists who were not involved in the study"</P>
<P>Quote: "the ultrasonic evaluations were performed blindly"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "all suspected recurrent VTE events, including those ruled out by local investigators, were adjudicated by a central, independent, blinded endpoint committee"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "all suspected outcome event and deaths were classified by central adjudication committees whose members were unaware of the treatment assignments"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Quote: "All suspected outcomes were classified by an independent blinded adjudication committee"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="13">
<NAME>Incomplete data outcome reported?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>91.5% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>% follow-up: from table 2, there were no participants lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>99% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>99% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>100% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>99% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>100% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>100% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>99.7% follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 08:03:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Not reported</P>
<P>Comment: probably no loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" NO="14">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" NO="15">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="16">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Abstract did not report bleeding events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Study not registered. No published protocol. All relevant outcomes listed in the methods section were reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Study not registered. No published protocol but a protocol is clearly mentioned in the discussion. All relevant outcomes listed in the methods section are reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Study not registered. No published protocol. All relevant outcomes listed in the methods section are reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Study not registered. No published protocol. All relevant outcomes listed in the methods section are reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Study not registered. No published protocol. All relevant outcomes listed in the methods section are reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Study is registered (<A HREF="http://clinicaltrials.gov/ct2/show/NCT00689520">NCT00689520</A>). All relevant outcomes listed on the registration page as well in the methods section of the published manuscript are reported on</P>
<P>Comment: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:36:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Study not registered. No published protocol. All relevant outcomes listed in the methods section are reported on</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Study is registered (<A HREF="http://clinicaltrials.gov/show/NCT00291330">NCT00291330</A>). All relevant outcomes listed on the registration page as well in the methods section of the published manuscript are reported on</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Post-hoc analysis. Study not registered. No published protocol. All relevant outcomes listed in the methods section are reported on except for non-fatal PE</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="17">
<NAME>Free of other bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:36:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 14:55:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>No other bias suspected</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit. </P>
<P>no other bias suspected</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Comment: study not reported as stopped early for benefit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>No other bias suspected</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:36:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-27 21:37:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-13 07:59:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Study not reported as stopped early for benefit</P>
<P>No other bias suspected</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-18" LEVEL="STUDY" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="18">
<NAME>Intention-to-treat analysis?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 21:22:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cesarone-2003">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Deitcher-2006">
<DESCRIPTION>
<P>Quote: "safety evaluations were performed on the safety populations defined as all randomised patients who received at least 1 dose of the study medication The intent to treat population included all patient in safety population who had at least 1 follow up measurement"</P>
<P>Quote: "of the 101 patients in the safety sample, 91 were included in the intend to treat analysis"</P>
<P>Comment: definitely no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-2006">
<DESCRIPTION>
<P>Only 1% lost to follow-up and all patients randomized included in the analyses of outcomes</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lee-2003">
<DESCRIPTION>
<P>Quote: "an analysis of efficacy end points was performed according to intention to treat principle and included all randomised patients who had a confirmed, qualifying thrombotic event and active cancer"</P>
<P>Comment: definitely yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopez_x002d_Beret-2001">
<DESCRIPTION>
<P>No loss to follow-up and all patients randomized included in the analyses of outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Meyer-2002">
<DESCRIPTION>
<P>Quote: "analysis was performed on an intention to treat basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Romera-2009">
<DESCRIPTION>
<P>Quote: "Two patients (one from each group) who developed symptoms of pulmonary embolism on the same day of randomisation were also included in the analysis"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2003">
<DESCRIPTION>
<P>Quote: "All analyses presented are based on the treatment period for the intention to treat population, which was defined as all patients from whom any data were available after randomizations, and who took at least one dose of the study medication"</P>
<P>Quote: "Five patients in each group were excluded from the intention-to-treat population since no data were available for them after randomizations"</P>
<P>Comment: probably yes (10 out of 1233 represents less than 1% of the study population)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Schulman-2009">
<DESCRIPTION>
<P>Quote: "we analysed efficacy to a modified intention to treat principle, since patients who did not receive any study drug were excluded from all analyses as prespecified in the protocol"</P>
<P>Comment: probably yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2010">
<DESCRIPTION>
<P>Quote: "The analyses were calculated in the intention to treat population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">Low molecular weight heparin compared with vitamin K antagonist for patients with cancer requiring long-term anticoagulation for venous thromboembolism</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Low molecular weight heparin compared with vitamin K antagonist for patients with cancer requiring long-term anticoagulation for venous thromboembolism</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with cancer requiring long-term anticoagulation for VTE<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> LMWH<BR/>
<B>Comparison: </B>VKA</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>VKA</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>Follow-up: 3-6 months (at any point)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>399 per 1000</P>
<P/>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>383 per 1000<BR/>(323 to 451)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR </B>0.96<BR/>(0.81 to 1.13)<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>897<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Recurrent VTE</B>
<BR/>Follow-up: 3-6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
<P>140 per 1000</P>
<P/>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>71 per 1000<BR/>(49 to 106)</P>
<P>
<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR </B>0.51<BR/>(0.35 to 0.76)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>964<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Major bleeding</B>
<BR/>Follow-up: 3-6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
<P>60 per 1000<BR/>
</P>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>64 per 1000<BR/>(31 to 131)<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR </B>1.07<BR/>(0.52 to 2.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1092<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Minor bleeding</B>
<BR/>Follow-up: 3-6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
<P>176 per 1000<BR/>
</P>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>156 per 1000<BR/>(90 to 272)<BR/>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR </B>0.89<BR/>(0.51 to 1.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1091<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Postphlebitic syndrome</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>LMWH:</B> low molecular weight heparin; <B>RR:</B> risk ratio; <B>VKA:</B> vitamin K antagonist; <B>VTE:</B> venous thromboembolism.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> CI includes values suggesting both no effect and values suggesting either benefit or harm.<BR/>
<SUP>2</SUP> We could not obtain data for subgroups of patients with cancer in 11 RCTs.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE>Glossary</TITLE>
<TABLE COLS="2" ROWS="19">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>Adjuvant therapy</P>
</TD>
<TD>
<P>A therapy given in addition to the primary treatment to decrease the risk of the cancer recurrence or to assist in the cure</P>
</TD>
</TR>
<TR>
<TD>
<P>Anticoagulation</P>
</TD>
<TD>
<P>The process of hindering the clotting of blood especially by treatment with an anticoagulant</P>
</TD>
</TR>
<TR>
<TD>
<P>Antithrombotic</P>
</TD>
<TD>
<P>Used against or tending to prevent thrombosis (clotting)</P>
</TD>
</TR>
<TR>
<TD>
<P>Coagulation</P>
</TD>
<TD>
<P>Clotting</P>
</TD>
</TR>
<TR>
<TD>
<P>Deep vein thrombosis (DVT)</P>
</TD>
<TD>
<P>A condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially life-threatening if dislodgment of the thrombus results in pulmonary embolism</P>
</TD>
</TR>
<TR>
<TD>
<P>Fondaparinux</P>
</TD>
<TD>
<P>An anticoagulant medication</P>
</TD>
</TR>
<TR>
<TD>
<P>Hemostatic system</P>
</TD>
<TD>
<P>The system that shortens the clotting time of blood and stops bleeding</P>
</TD>
</TR>
<TR>
<TD>
<P>Heparin</P>
</TD>
<TD>
<P>An enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH)</P>
</TD>
</TR>
<TR>
<TD>
<P>Impedance plethysmography</P>
</TD>
<TD>
<P>A technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment</P>
</TD>
</TR>
<TR>
<TD>
<P>Kappa statistic</P>
</TD>
<TD>
<P>A measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both</P>
</TD>
</TR>
<TR>
<TD>
<P>Metastasis</P>
</TD>
<TD>
<P>The spread of a cancer cells from the initial or primary site of disease to another part of the body</P>
</TD>
</TR>
<TR>
<TD>
<P>Parenteral nutrition</P>
</TD>
<TD>
<P>The practice of feeding a patient intravenously, circumventing the gastrointestinal tract</P>
</TD>
</TR>
<TR>
<TD>
<P>Pulmonary embolism (PE)</P>
</TD>
<TD>
<P>Embolism of a pulmonary artery or one of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombocytopenia</P>
</TD>
<TD>
<P>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombosis</P>
</TD>
<TD>
<P>The formation or presence of a blood clot within a blood vessel</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin K antagonists<BR/>
</P>
</TD>
<TD>
<P>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Warfarin</P>
</TD>
<TD>
<P>An anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation</P>
</TD>
</TR>
<TR>
<TD>
<P>Ximelagatran</P>
</TD>
<TD>
<P>An anticoagulant medication</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<COMPARISON ID="CMP-001" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<NAME>Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA)</NAME>
<IV_OUTCOME CHI2="1.1912721918292364" CI_END="1.1353309091497876" CI_START="0.811320440851233" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.9597484950357759" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.05512246159277327" LOG_CI_START="-0.09080758203143527" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.017842560219331043" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="0.5512120625662933" P_Q="1.0" P_Z="0.6317384773548255" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="503" TOTAL_2="506" WEIGHT="100.0" Z="0.4792813673369525">
<NAME>Survival (time-to-event)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.437366392180678" CI_START="0.6385134461277551" EFFECT_SIZE="0.958007185995754" ESTIMABLE="YES" ESTIMATE="-0.0429" LOG_CI_END="0.15756748617182564" LOG_CI_START="-0.1948299527191247" LOG_EFFECT_SIZE="-0.01863123327364951" MODIFIED="2014-04-15 14:07:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.207" STUDY_ID="STD-Hull-2006" TOTAL_1="100" TOTAL_2="99" WEIGHT="17.1484131287201"/>
<IV_DATA CI_END="1.2116661530856618" CI_START="0.8187337017797562" EFFECT_SIZE="0.9960079893439915" ESTIMABLE="YES" ESTIMATE="-0.0040" LOG_CI_END="0.0833829763938726" LOG_CI_START="-0.08685733224909857" LOG_EFFECT_SIZE="-0.001737177927613002" ORDER="2" SE="0.1" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="336" WEIGHT="73.47923541525276"/>
<IV_DATA CI_END="1.2464380401312336" CI_START="0.41590853292569185" EFFECT_SIZE="0.7200029282258205" ESTIMABLE="YES" ESTIMATE="-0.3285" LOG_CI_END="0.09567069479494149" LOG_CI_START="-0.3810021694053779" LOG_EFFECT_SIZE="-0.14266573730521823" MODIFIED="2014-04-15 14:25:28 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.28" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" WEIGHT="9.372351456027138"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.4025582751504126" CI_END="1.2830036182920077" CI_START="0.45870705092839403" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7671524008156305" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="39" I2="16.7554010786777" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.10822788116217484" LOG_CI_START="-0.33846458414148844" LOG_EFFECT_SIZE="-0.1151183514896568" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="0.30080925227585276" P_Q="1.0" P_Z="0.3123920754183783" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03941222444072768" TOTALS="YES" TOTAL_1="263" TOTAL_2="256" WEIGHT="100.0" Z="1.0102154856181316">
<NAME>Mortality (at 3 months)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.49000900118621" CI_START="0.10219869994456182" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5428265470624637" LOG_CI_START="-0.9905546287658276" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2014-04-16 09:43:16 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.9007156930407744" STUDY_ID="STD-Cesarone-2003" TOTAL_1="96" TOTAL_2="86" VAR="0.8112887596899224" WEIGHT="8.093111480743685"/>
<DICH_DATA CI_END="1.8299781743300492" CI_START="0.5934406184374089" EFFECT_SIZE="1.0421052631578946" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.26244591004488377" LOG_CI_START="-0.22662273142747952" LOG_EFFECT_SIZE="0.01791158930870211" MODIFIED="2014-04-16 10:09:44 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.2872813409296857" STUDY_ID="STD-Hull-2006" TOTAL_1="100" TOTAL_2="99" VAR="0.08253056884635833" WEIGHT="56.4594078564283"/>
<DICH_DATA CI_END="1.0783046636072018" CI_START="0.23062572021442945" EFFECT_SIZE="0.4986830553116769" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.03274148351283535" LOG_CI_START="-0.6370922602489983" LOG_EFFECT_SIZE="-0.3021753883680815" MODIFIED="2014-03-18 13:17:13 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.39346365681620815" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.15481364923518284" WEIGHT="35.44748066282802"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.225845246495881" CI_END="1.1271224662312476" CI_START="0.8102144740709457" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9556207072845887" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="176" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.051971106391173784" LOG_CI_START="-0.09140000263231964" LOG_EFFECT_SIZE="-0.01971444812057292" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="0.5417654645506174" P_Q="1.0" P_Z="0.5898763226955428" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="441" WEIGHT="100.00000000000001" Z="0.5390152668076892">
<NAME>Mortality (at 6 months)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.147245696688997" CI_START="0.6790886434504422" EFFECT_SIZE="1.2075471698113207" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.33188174104138335" LOG_CI_START="-0.16807353227518712" LOG_EFFECT_SIZE="0.08190410438309811" MODIFIED="2014-03-18 13:20:21 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.2936762023646698" STUDY_ID="STD-Deitcher-2006" TOTAL_1="53" TOTAL_2="32" VAR="0.08624571183533447" WEIGHT="8.223581149289146"/>
<DICH_DATA CI_END="1.1593860095323834" CI_START="0.7975091569002221" EFFECT_SIZE="0.9615721288515406" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="136" LOG_CI_END="0.06422805537618388" LOG_CI_START="-0.09826432172732398" LOG_EFFECT_SIZE="-0.01701813317557005" MODIFIED="2014-03-18 13:28:58 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.09544882666083958" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="338" VAR="0.009110478510931" WEIGHT="77.84976488393058"/>
<DICH_DATA CI_END="1.2511223345488705" CI_START="0.5165551322699002" EFFECT_SIZE="0.8039114770972723" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.09729977701712296" LOG_CI_START="-0.2868833191341249" LOG_EFFECT_SIZE="-0.09479177105850098" MODIFIED="2014-03-18 13:20:40 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.22567105241623975" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.05092742389865323" WEIGHT="13.92665396678029"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.902289433426069" CI_END="1.1128714349432238" CI_START="0.8388452851179491" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9661919872078063" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="232" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.04644499513453886" LOG_CI_START="-0.07631813215761907" LOG_EFFECT_SIZE="-0.014936568511540098" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="0.862493274712625" P_Q="1.0" P_Z="0.633407014222831" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="668" TOTAL_2="642" WEIGHT="100.0" Z="0.4769369595084223">
<NAME>Mortality (at any time point)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.49000900118621" CI_START="0.10219869994456182" EFFECT_SIZE="0.5972222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5428265470624637" LOG_CI_START="-0.9905546287658276" LOG_EFFECT_SIZE="-0.22386404085168193" MODIFIED="2014-03-21 08:20:08 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.9007156930407744" STUDY_ID="STD-Cesarone-2003" TOTAL_1="96" TOTAL_2="86" VAR="0.8112887596899224" WEIGHT="0.6409669423657255"/>
<DICH_DATA CI_END="2.147245696688997" CI_START="0.6790886434504422" EFFECT_SIZE="1.2075471698113207" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.33188174104138335" LOG_CI_START="-0.16807353227518712" LOG_EFFECT_SIZE="0.08190410438309811" MODIFIED="2014-03-18 13:36:26 +0000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.2936762023646698" STUDY_ID="STD-Deitcher-2006" TOTAL_1="53" TOTAL_2="32" VAR="0.08624571183533447" WEIGHT="6.029392819749284"/>
<DICH_DATA CI_END="1.3404704771928493" CI_START="0.7460067319752938" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="47" LOG_CI_END="0.12725725343010497" LOG_CI_START="-0.12725725343010497" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-21 08:55:43 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.14950308119681513" STUDY_ID="STD-Hull-2006" TOTAL_1="99" TOTAL_2="99" VAR="0.022351171287341494" WEIGHT="23.265414997228216"/>
<DICH_DATA CI_END="1.152317267608114" CI_START="0.7929335942009849" EFFECT_SIZE="0.9558823529411765" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="136" LOG_CI_END="0.0615720698868614" LOG_CI_START="-0.10076318201362287" LOG_EFFECT_SIZE="-0.019595556063380724" ORDER="13" O_E="0.0" SE="0.09535653053880122" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="336" VAR="0.009092867916397329" WEIGHT="57.188697829470236"/>
<DICH_DATA CI_END="2.936231249047936" CI_START="0.5196973356877838" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.46779025636343524" LOG_CI_START="-0.2842495096521445" LOG_EFFECT_SIZE="0.09177037335564536" ORDER="14" O_E="0.0" SE="0.4417518812144316" STUDY_ID="STD-Lopez_x002d_Beret-2001" TOTAL_1="17" TOTAL_2="18" VAR="0.19514472455648926" WEIGHT="2.664736527497583"/>
<DICH_DATA CI_END="1.2511223345488705" CI_START="0.5165551322699002" EFFECT_SIZE="0.8039114770972723" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.09729977701712296" LOG_CI_START="-0.2868833191341249" LOG_EFFECT_SIZE="-0.09479177105850098" MODIFIED="2014-03-18 13:37:42 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.22567105241623975" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.05092742389865323" WEIGHT="10.210790883688956"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.2787697273663881" CI_END="0.7120090601295442" CI_START="0.3167761305010025" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.474918387672548" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.14751448004399775" LOG_CI_START="-0.49924755051136743" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.32338101527768265" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="5" P_CHI2="0.8698931827742508" P_Q="1.0" P_Z="3.134109018732292E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="502" TOTAL_2="506" WEIGHT="100.00000000000001" Z="3.6039553652777947">
<NAME>Recurrent venous thromboembolism (time-to-event)</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<EFFECT_MEASURE>HR</EFFECT_MEASURE>
<IV_DATA CI_END="1.0099326171815268" CI_START="0.16970670222617376" EFFECT_SIZE="0.41399557235860107" ESTIMABLE="YES" ESTIMATE="-0.8819" LOG_CI_END="0.00429239857228167" LOG_CI_START="-0.7703010057532372" LOG_EFFECT_SIZE="-0.3830043035904778" MODIFIED="2014-04-16 10:11:31 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.455" STUDY_ID="STD-Hull-2006" TOTAL_1="99" TOTAL_2="99" WEIGHT="20.619532631882077"/>
<IV_DATA CI_END="0.768274149750696" CI_START="0.29987446068509305" EFFECT_SIZE="0.479985204266536" ESTIMABLE="YES" ESTIMATE="-0.734" LOG_CI_END="-0.1144837793454214" LOG_CI_START="-0.5230605200885522" LOG_EFFECT_SIZE="-0.31877214971698686" ORDER="17" SE="0.24" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="336" WEIGHT="74.11039484575326"/>
<IV_DATA CI_END="4.084778834994364" CI_START="0.11995152380774451" EFFECT_SIZE="0.699982460976843" ESTIMABLE="YES" ESTIMATE="-0.3567" LOG_CI_END="0.6111685471984805" LOG_CI_START="-0.9209942305882604" LOG_EFFECT_SIZE="-0.15491284169488992" MODIFIED="2014-04-16 10:11:44 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.9" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" WEIGHT="5.270072522364676"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="1.3935443718063103" CI_END="0.7110073679647382" CI_START="0.3486094648915136" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4978593155501973" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.14812589877818175" LOG_CI_START="-0.45766082579070116" LOG_EFFECT_SIZE="-0.3028933622844414" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="6" P_CHI2="0.8453163133756292" P_Q="1.0" P_Z="1.2514620923098591E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="591" TOTAL_2="571" WEIGHT="100.0" Z="3.8358196728457528">
<NAME>Recurrent venous thromboembolism</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.368013570165133" CI_START="0.19242073002928178" EFFECT_SIZE="0.8050314465408805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5273738326601425" LOG_CI_START="-0.7157481420053087" LOG_EFFECT_SIZE="-0.0941871546725831" MODIFIED="2014-03-18 13:42:39 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.7302160014715039" STUDY_ID="STD-Deitcher-2006" TOTAL_1="53" TOTAL_2="32" VAR="0.5332154088050314" WEIGHT="6.200002065489323"/>
<DICH_DATA CI_END="1.0168271799316475" CI_START="0.18823872313569212" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.007247146452884367" LOG_CI_START="-0.7252910317362203" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2014-04-21 14:07:16 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.4302965519907435" STUDY_ID="STD-Hull-2006" TOTAL_1="99" TOTAL_2="99" VAR="0.18515512265512263" WEIGHT="17.854956365964007"/>
<DICH_DATA CI_END="0.7894635243019488" CI_START="0.32873331562420827" EFFECT_SIZE="0.5094339622641509" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="53" LOG_CI_END="-0.10266793096327162" LOG_CI_START="-0.4831562799203319" LOG_EFFECT_SIZE="-0.29291210544180174" MODIFIED="2010-10-27 21:27:05 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.22350073962508035" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="336" VAR="0.04995258061295796" WEIGHT="66.18149844063012"/>
<DICH_DATA CI_END="4.097175578562362" CI_START="0.12181478373231959" EFFECT_SIZE="0.7064676616915423" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6124845754168716" LOG_CI_START="-0.9143000014917363" LOG_EFFECT_SIZE="-0.1509077130374324" MODIFIED="2014-03-18 13:43:59 +0000" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.8968408181816612" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.8043234531567514" WEIGHT="4.110207930611775"/>
<DICH_DATA CI_END="1.172365194909606" CI_START="0.05850916131443062" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.0690629166556214" LOG_CI_START="-1.2327761271349722" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2011-02-18 20:36:28 +0000" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.7647066985297923" STUDY_ID="STD-Romera-2009" TOTAL_1="36" TOTAL_2="33" VAR="0.5847763347763347" WEIGHT="5.653335197304766"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.559492950667028" CI_END="2.1931363484548307" CI_START="0.5232138496822473" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0712046077912092" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="32" I2="46.038244375504426" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.3410656328361116" LOG_CI_START="-0.281320768581022" LOG_EFFECT_SIZE="0.02987243212754475" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="7" P_CHI2="0.13512337576033928" P_Q="1.0" P_Z="0.8507643807562938" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23740151552366787" TOTALS="YES" TOTAL_1="556" TOTAL_2="536" WEIGHT="99.99999999999999" Z="0.1881432208907293">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.738453081019387" CI_START="0.4566540679443024" EFFECT_SIZE="3.6226415094339623" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4584633874426725" LOG_CI_START="-0.3404126692371514" LOG_EFFECT_SIZE="0.5590253591027605" MODIFIED="2014-03-18 13:46:48 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="1.0566687002738204" STUDY_ID="STD-Deitcher-2006" TOTAL_1="53" TOTAL_2="32" VAR="1.1165487421383649" WEIGHT="9.871716737625592"/>
<DICH_DATA CI_END="2.746457979108561" CI_START="0.3641053340727164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4387729586892967" LOG_CI_START="-0.43877295868929667" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-21 12:25:27 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.5154748157905347" STUDY_ID="STD-Hull-2006" TOTAL_1="100" TOTAL_2="100" VAR="0.2657142857142857" WEIGHT="26.56607760596507"/>
<DICH_DATA CI_END="3.181013659142689" CI_START="0.7740857774577927" EFFECT_SIZE="1.5691964285714286" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.502565533954129" LOG_CI_START="-0.11121091191076903" LOG_EFFECT_SIZE="0.19567731102167996" MODIFIED="2014-03-18 13:47:08 +0000" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.3605353225434483" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="333" VAR="0.12998571880150828" WEIGHT="36.3807235845452"/>
<DICH_DATA CI_END="1.1864171916249604" CI_START="0.16432633812168396" EFFECT_SIZE="0.44154228855721395" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.07423743115397428" LOG_CI_START="-0.7842928225406887" LOG_EFFECT_SIZE="-0.3550276956933572" MODIFIED="2014-03-18 13:47:23 +0000" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.5043049208135406" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.2543234531567515" WEIGHT="27.181482071864135"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.80625780578568" CI_END="1.5460525381977344" CI_START="0.5080217820346093" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8862439650425519" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="94" I2="76.57395278545272" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.189224248095679" LOG_CI_START="-0.2941176664274348" LOG_EFFECT_SIZE="-0.0524467091658779" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="8" P_CHI2="0.00507488925200017" P_Q="1.0" P_Z="0.6705848096437452" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23116832283716157" TOTALS="YES" TOTAL_1="556" TOTAL_2="535" WEIGHT="99.99999999999999" Z="0.42534552863758207">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9917812885852941" CI_START="0.9632476110180617" EFFECT_SIZE="1.3851276359600444" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="17" LOG_CI_END="0.2992416481562742" LOG_CI_START="-0.01626205942158984" LOG_EFFECT_SIZE="0.14148979436734221" MODIFIED="2014-03-18 13:58:52 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.18532843959977774" STUDY_ID="STD-Deitcher-2006" TOTAL_1="53" TOTAL_2="32" VAR="0.03434663052448847" WEIGHT="30.359536379538024"/>
<DICH_DATA CI_END="2.0881319194544887" CI_START="0.6496427643048198" EFFECT_SIZE="1.1647058823529413" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.3197579321086588" LOG_CI_START="-0.18732539434214443" LOG_EFFECT_SIZE="0.06621626888325721" MODIFIED="2014-04-21 12:22:24 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.29786325606015024" STUDY_ID="STD-Hull-2006" TOTAL_1="100" TOTAL_2="99" VAR="0.08872251931075462" WEIGHT="25.19894233848378"/>
<DICH_DATA CI_END="0.8409545146444368" CI_START="0.3520571073526003" EFFECT_SIZE="0.5441176470588235" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="51" LOG_CI_END="-0.0752274935875157" LOG_CI_START="-0.453386883690967" LOG_EFFECT_SIZE="-0.26430718863924135" MODIFIED="2014-03-18 13:59:40 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.22213269766593827" STUDY_ID="STD-Lee-2003" TOTAL_1="336" TOTAL_2="333" VAR="0.04934293537234713" WEIGHT="28.73649684275349"/>
<DICH_DATA CI_END="1.6672911410751161" CI_START="0.20787900968367068" EFFECT_SIZE="0.5887230514096186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.2220114426127832" LOG_CI_START="-0.6821893607828976" LOG_EFFECT_SIZE="-0.23008895908505722" MODIFIED="2014-03-18 14:00:06 +0000" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.5311320277807856" STUDY_ID="STD-Meyer-2002" TOTAL_1="67" TOTAL_2="71" VAR="0.28210123093452927" WEIGHT="15.705024439224692"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5472443646409774" CI_END="1.6613052421963654" CI_START="0.5749268433758239" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9773070033411533" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.22044943547503892" LOG_CI_START="-0.24038741363992366" LOG_EFFECT_SIZE="-0.009968989082442365" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="9" P_CHI2="0.45944592891921177" P_Q="1.0" P_Z="0.932422542547457" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="170" WEIGHT="100.0" Z="0.08479729692356157">
<NAME>Thrombocytopenia</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>VKA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors LMWH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors VKA</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.102200374739404" CI_START="0.43221058328439976" EFFECT_SIZE="1.485" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7077575103174496" LOG_CI_START="-0.3643046030109871" LOG_EFFECT_SIZE="0.1717264536532312" MODIFIED="2014-03-21 10:19:43 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.6297345921621715" STUDY_ID="STD-Hull-2006" TOTAL_1="100" TOTAL_2="99" VAR="0.3965656565656565" WEIGHT="18.477980330611267"/>
<DICH_DATA CI_END="1.5997308853468484" CI_START="0.49391023454473815" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.20404692963157584" LOG_CI_START="-0.3063519745263384" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2014-03-18 14:11:46 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.2998108428176815" STUDY_ID="STD-Meyer-2002" TOTAL_1="71" TOTAL_2="71" VAR="0.08988654147104852" WEIGHT="81.52201966938873"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<NAME>Dabigatran versus vitamin K antagonist</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6064233192246533" CI_START="0.3043300314167544" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.890625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4160449525404336" LOG_CI_START="-0.5166551891632252" LOG_EFFECT_SIZE="-0.05030511831139577" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8325587351216726" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.21142104674342055">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Dabigatran</GROUP_LABEL_1>
<GROUP_LABEL_2>Warfarin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors dabigatran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors warfarin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6064233192246533" CI_START="0.3043300314167544" EFFECT_SIZE="0.890625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4160449525404336" LOG_CI_START="-0.5166551891632252" LOG_EFFECT_SIZE="-0.05030511831139577" MODIFIED="2010-11-01 18:11:06 +0000" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.5478726801768916" STUDY_ID="STD-Schulman-2009" TOTAL_1="64" TOTAL_2="57" VAR="0.3001644736842105" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.42783324432536" CI_START="0.1028460363652795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.59375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5350196864043556" LOG_CI_START="-0.9878124411385096" LOG_EFFECT_SIZE="-0.22639637736707702" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5600496435079843" Q="0.0" RANDOM="YES" SCALE="330.95" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="99.99999999999999" Z="0.5827677757045742">
<NAME>Recurrent venous thromboembolism</NAME>
<GROUP_LABEL_1>Dabigatran</GROUP_LABEL_1>
<GROUP_LABEL_2>Warfarin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors dabigatran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors warfarin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.42783324432536" CI_START="0.1028460363652795" EFFECT_SIZE="0.59375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5350196864043556" LOG_CI_START="-0.9878124411385096" LOG_EFFECT_SIZE="-0.22639637736707702" MODIFIED="2010-11-01 18:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.894519129859284" STUDY_ID="STD-Schulman-2009" TOTAL_1="64" TOTAL_2="57" VAR="0.8001644736842104" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.93653457684375" CI_START="0.37115409875982824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.484375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.7735330016577739" LOG_CI_START="-0.4304457390478527" LOG_EFFECT_SIZE="0.1715436313049606" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5764936222654886" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="0.5585137474070172">
<NAME>Major bleeding</NAME>
<GROUP_LABEL_1>Dabigatran</GROUP_LABEL_1>
<GROUP_LABEL_2>Warfarin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors dabigatran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors warfarin</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.93653457684375" CI_START="0.37115409875982824" EFFECT_SIZE="1.484375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7735330016577739" LOG_CI_START="-0.4304457390478527" LOG_EFFECT_SIZE="0.1715436313049606" MODIFIED="2010-11-01 18:12:15 +0000" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.7072230720813699" STUDY_ID="STD-Schulman-2009" TOTAL_1="64" TOTAL_2="57" VAR="0.5001644736842106" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="118.38343683162026" CI_START="0.32955993603491757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.246153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="2.0732909439762777" LOG_CI_START="-0.48206559010760086" LOG_EFFECT_SIZE="0.7956126769343386" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.22228553343103763" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="57" WEIGHT="100.0" Z="1.220473285536146">
<NAME>Thrombocytopenia</NAME>
<GROUP_LABEL_1>Dabigatran</GROUP_LABEL_1>
<GROUP_LABEL_2>Warfarin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors dabigatran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors warfarin</GRAPH_LABEL_2>
<DICH_DATA CI_END="118.38343683162026" CI_START="0.32955993603491757" EFFECT_SIZE="6.246153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0732909439762777" LOG_CI_START="-0.48206559010760086" LOG_EFFECT_SIZE="0.7956126769343386" MODIFIED="2010-11-01 18:13:04 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.5010290773397181" STUDY_ID="STD-Schulman-2009" TOTAL_1="64" TOTAL_2="57" VAR="2.2530882910193255" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="3">
<NAME>Ximelagtran versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.906481837378824" CI_START="0.25208172557262676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.8979832776186797" LOG_CI_START="-0.5984586369520155" LOG_EFFECT_SIZE="0.14976232033333212" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6948349130836934" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="0.39230223537101366">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Ximelagtran</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ximelagtran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.906481837378824" CI_START="0.25208172557262676" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8979832776186797" LOG_CI_START="-0.5984586369520155" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2014-04-23 07:39:13 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.8790173881257702" STUDY_ID="STD-Schulman-2003" TOTAL_1="34" TOTAL_2="32" VAR="0.7726715686274509" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6249379820707937" CI_START="0.44076486649859214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0756302521008403" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.4191190470324105" LOG_CI_START="-0.35579303052173533" LOG_EFFECT_SIZE="0.03166300825533759" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8727481324603528" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.0" Z="0.16016876654840848">
<NAME>Minor bleeding</NAME>
<GROUP_LABEL_1>Ximelagtran</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ximelagtran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6249379820707937" CI_START="0.44076486649859214" EFFECT_SIZE="1.0756302521008403" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4191190470324105" LOG_CI_START="-0.35579303052173533" LOG_EFFECT_SIZE="0.03166300825533759" MODIFIED="2014-04-23 07:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.45518719023195336" STUDY_ID="STD-Schulman-2003" TOTAL_1="34" TOTAL_2="32" VAR="0.2071953781512605" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.941379215836193" CI_START="0.04481608828715585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.6938481841920884" LOG_CI_START="-1.3485660529647492" LOG_EFFECT_SIZE="-0.32735893438633035" METHOD="MH" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5298155877931754" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6282875527814377">
<NAME>Recurrent venous thromboembolism</NAME>
<GROUP_LABEL_1>Ximelagtran</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors ximelagtran</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.941379215836193" CI_START="0.04481608828715585" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6938481841920884" LOG_CI_START="-1.3485660529647492" LOG_EFFECT_SIZE="-0.32735893438633035" MODIFIED="2014-04-23 07:42:07 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="1.1997242330194542" STUDY_ID="STD-Schulman-2003" TOTAL_1="34" TOTAL_2="32" VAR="1.4393382352941178" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-06-04 10:24:04 +0100" MODIFIED_BY="Gail Quinn">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAT8CAYAAACpRAZ3AAB8ZUlEQVR42uydf2RW7x//P0ySmYmZ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-06-04 10:24:04 +0100" MODIFIED_BY="Gail Quinn" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiIAAAFkCAMAAAAqg6D0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-06-04 10:24:04 +0100" MODIFIED_BY="Gail Quinn" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgments about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAc8AAAJFCAIAAAA02etfAAAoOElEQVR42u3dsW4jNx7HcQEBghQq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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-06-04 10:24:02 +0100" MODIFIED_BY="Gail Quinn" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA), outcome: 1.1 Survival (time-to-event).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-06-04 10:24:02 +0100" MODIFIED_BY="Gail Quinn" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA), outcome: 1.4 Mortality (at any time point).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-06-04 10:24:02 +0100" MODIFIED_BY="Gail Quinn" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA), outcome: 1.5 Recurrent venous thromboembolism (time-to-event).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-06-04 10:24:02 +0100" MODIFIED_BY="Gail Quinn" NO="7" REF_ID="CMP-001.08" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA), outcome: 1.7 Bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAADACAMAAABCvzcFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2014-06-04 10:24:02 +0100" MODIFIED_BY="Gail Quinn" NO="8" REF_ID="CMP-001.07" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Low molecular weight heparin (LMWH) versus vitamin K antagonist (VKA), outcome: 1.7 Major bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAADACAMAAABCvzcFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-02-18 21:44:49 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-06-19 09:05:59 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE MODIFIED="2011-02-18 21:42:49 +0000" MODIFIED_BY="[Empty name]">Full search strategies for the electronic databases</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-04 10:23:55 +0100" MODIFIED_BY="Gail Quinn">
<TABLE COLS="2" ROWS="5">
<TR>
<TH VALIGN="BOTTOM">
<P>Database</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>Cochrane Central Register of Controlled Trials (CENTRAL) (latest issue)</P>
</TD>
<TD>
<P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta<BR/>#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban</P>
<P>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor<BR/>#8 6 AND 7<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<P>#1 Heparin/<BR/>#2 Heparin.tw<BR/>#3 Heparin, Low-Molecular-Weight/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarins/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 (fondaparinux OR Arixtra).tw<BR/>#11 (ximelagatran OR Exanta).tw</P>
<P>#12 (Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban).tw.<BR/>#13 5 OR 9 OR 10 OR 11 OR 12<BR/>#14 Neoplasms/<BR/>#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor).tw<BR/>#16 14 OR 15<BR/>#17 clinical trial.pt. OR random:.tw. OR tu.xs.<BR/>#18 animals/ NOT human/<BR/>#19 17 NOT 18<BR/>#20 13 AND 16 AND 19<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<P>#1 Heparin/<BR/>#2 heparin.tw<BR/>#3 Low Molecular Weight Heparin/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarin derivative/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 fondaparinux/<BR/>#11 (fondaparinux OR Arixtra).tw<BR/>#12 ximelagatran/<BR/>#13 (ximelagatran OR Exanta).tw</P>
<P>#14 (Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban).tw.<BR/>#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14<BR/>#16 Neoplasm/<BR/>#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor).tw<BR/>#18 16 OR 17<BR/>#19 Random:.tw. OR clinical trial:.mp. OR exp health care quality<BR/>#20 animals/ NOT human/<BR/>#21 19 NOT 20<BR/>#22 15 AND 18 AND 21<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ISI (International Scientific Information) the Web of Science</P>
</TD>
<TD VALIGN="TOP">
<P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta</P>
<P>#5 Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban<BR/>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor<BR/>#8 random$ OR placebo$ OR versus OR vs OR double blind OR double-blind OR compar$ OR controlled<BR/>#9 6 AND 7 AND 8<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<TITLE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">Full search strategies for electronic databases - update 2013</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL (issue 12, 2012)</P>
</TD>
<TD>
<P>#1 MeSH descriptor: [Heparin] explode all trees</P>
<P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum)</P>
<P>#3 MeSH descriptor: [Coumarins] explode all trees</P>
<P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA)</P>
<P>#5 (fondaparinux or arixtra)</P>
<P>#6 (ximelagatran or exanta)</P>
<P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban)</P>
<P>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7</P>
<P>#9 MeSH descriptor: [Neoplasms] explode all trees</P>
<P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*)</P>
<P>#11 #9 or #10</P>
<P>#12 #8 and #10<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>#1 exp Heparin/</P>
<P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P>
<P>#3 exp Coumarins/</P>
<P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P>
<P>#5 (fondaparinux or arixtra).tw.</P>
<P>#6 (ximelagatran or exanta).tw.</P>
<P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P>
<P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
<P>#9 exp Neoplasms/</P>
<P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P>
<P>#11 9 or 10</P>
<P>#12 8 and 11</P>
<P>#13 randomised controlled trial.pt.</P>
<P>#14 controlled clinical trial.pt.</P>
<P>#15 randomized.ab.</P>
<P>#16 placebo.ab.</P>
<P>#17 drug therapy.fs.</P>
<P>#18 randomly.ab.</P>
<P>#19 trial.ab.</P>
<P>#20 groups.ab.</P>
<P>#21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20</P>
<P>#22 12 and 21</P>
<P>#23 exp animals/ not humans.sh.</P>
<P>#24 22 not 23</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>#1 heparin/</P>
<P>#2 exp low molecular weight heparin/</P>
<P>#3 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P>
<P>#4 exp coumarin derivative/</P>
<P>#5 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P>
<P>#6 (fondaparinux or arixtra).tw.</P>
<P>#7 (ximelagatran or exanta).tw.</P>
<P>#8 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P>
<P>#9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
<P>#10 exp neoplasm/</P>
<P>#11 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P>
<P>#12 10 or 11</P>
<P>#13 9 and 12</P>
<P>#14 crossover procedure/</P>
<P>#15 double-blind procedure/</P>
<P>#16 randomised controlled trial/</P>
<P>#17 single-blind procedure/</P>
<P>#18 random*.mp.</P>
<P>#19 factorial*.mp.</P>
<P>#20 (crossover* or cross over* or cross-over*).mp.</P>
<P>#21 placebo*.mp.</P>
<P>#22 (double* adj blind*).mp.</P>
<P>#23 (singl* adj blind*).mp.</P>
<P>#24 assign*.mp.</P>
<P>#25 allocat*.mp.</P>
<P>#26 volunteer*.mp.</P>
<P>#27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26</P>
<P>#28 13 and 27</P>
<P>#29 (exp animal/ or nonhuman/ or exp animal experiment/) not human/</P>
<P>#30 28 not 29</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-06-19 09:05:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-06-04 10:23:56 +0100" MODIFIED_BY="Gail Quinn">Detailed statistical data abstraction</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-19 09:05:59 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="13" ROWS="7">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Mortality at 3 months</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cesarone 2003</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>86</P>
</TD>
</TR>
<TR>
<TD>
<P>Hull 2006</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5] "8 (4 in each group) were considered not evaluable by the outcome adjudication committee" (Applies to both arms)</P>
<TABLE COLS="13" ROWS="8">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Mortality at 6 months</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Deitcher 2006</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>32+36=68</P>
</TD>
<TD>
<P>1+5+4=10</P>
</TD>
<TD>
<P>3+2=5</P>
</TD>
<TD>
<P>10+19=29</P>
</TD>
<TD>
<P>68-10-5=53</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>34-2=32</P>
</TD>
</TR>
<TR>
<TD>
<P>Lee A, 2003</P>
</TD>
<TD>
<P>130</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[6]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Doormal 2010</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]&#8220;Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed pulmonary embolism&#8221;</P>
<P>[6 ]"8 (4 in each group) were considered not evaluable by the outcome adjudication committee" (Applies to both arms)</P>
<TABLE COLS="13" ROWS="11">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Mortality at any point</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cesarone 2003</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>86</P>
</TD>
</TR>
<TR>
<TD>
<P>Hull 2006</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
</TR>
<TR>
<TD>
<P>Van Doormal 2010</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P>Lee A, 2003</P>
</TD>
<TD>
<P>130</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
</TR>
<TR>
<TD>
<P>Deitcher 2006</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>32+36=68</P>
</TD>
<TD>
<P>1+5+4=10</P>
</TD>
<TD>
<P>3+2=5</P>
</TD>
<TD>
<P>10+19=29</P>
</TD>
<TD>
<P>68-10-5=53</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>34-2=32</P>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[6]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
<TR>
<TD>
<P>Lopez-Beret 2001</P>
</TD>
<TD>
<P>7[7]</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>18</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]&#8220;Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed pulmonary embolism&#8221;</P>
<P>[6] "8 (4 in each group) were considered not evaluable by the outcome adjudication committee" (Applies to both arms)</P>
<P>[7]"Thirteen patients with cancer at an advanced stage died because of the progression of their neoplastic disease: seven (41.2%) of 17 patients with malignancy in the LMWH group and six (33.3%) of 18 with cancer in the OA group."</P>
<TABLE COLS="13" ROWS="10">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Recurrent VTE</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name </B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Romera 2009</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>33</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Deitcher 2006</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>32+36=68</P>
</TD>
<TD>
<P>1+5+4=10</P>
</TD>
<TD>
<P>3+2=5</P>
</TD>
<TD>
<P>10+19=29</P>
</TD>
<TD>
<P>68-10-5=53</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>34-2=32</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hull 2006</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Van Doormaal 2010</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lee A, 2003</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>338</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Meyer 2002</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[6]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]&#8220;Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed pulmonary embolism&#8221;</P>
<P>[6] "8 (4 in each group) were considered not evaluable by the outcome adjudication committee" (Applies to both arms)</P>
<TABLE COLS="13" ROWS="9">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Major Bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name </B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Van Doormaal 2010</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P>Deitcher 2006</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>32+36=68</P>
</TD>
<TD>
<P>1+5+4=10</P>
</TD>
<TD>
<P>3+2=5</P>
</TD>
<TD>
<P>10+19=29</P>
</TD>
<TD>
<P>68-10-5=53</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>34-2=32</P>
</TD>
</TR>
<TR>
<TD>
<P>Hull 2006</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
</TR>
<TR>
<TD>
<P>Lee A, 2003</P>
</TD>
<TD>
<P/>
<P>19</P>
</TD>
<TD>
<P/>
<P>338</P>
</TD>
<TD>
<P/>
<P>0</P>
</TD>
<TD>
<P>2[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
<TD>
<P/>
<P>12</P>
</TD>
<TD>
<P/>
<P>338</P>
</TD>
<TD>
<P/>
<P>3[6]</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2-3=333</P>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[7]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]&#8220;Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed pulmonary embolism&#8221;</P>
<P>[6]&#8220;Three patients assigned to oral anticoagulant therapy did not receive the study drug and were excluded from the safety analyses. Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4 percent) had major bleeding&#8221;</P>
<P>[7] "8 (4 in each group) were considered not evaluable by the outcome adjudication committee"(Applies to both arms)</P>
<TABLE COLS="13" ROWS="9">
<TR>
<TD COLSPAN="13" VALIGN="TOP">
<P>
<B>Outcome: Minor Bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name </B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>van Doormaal 2010</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>220</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>201</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P>Deitcher 2006</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>32+36=68</P>
</TD>
<TD>
<P>1+5+4=10</P>
</TD>
<TD>
<P>3+2=5</P>
</TD>
<TD>
<P>10+19=29</P>
</TD>
<TD>
<P>68-10-5=53</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>34-2=32</P>
</TD>
</TR>
<TR>
<TD>
<P>Hull 2006</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[6]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
</TR>
<TR>
<TD>
<P>Lee A, 2003</P>
</TD>
<TD>
<P/>
<P>28[7]</P>
</TD>
<TD>
<P/>
<P>338</P>
</TD>
<TD>
<P/>
<P>0</P>
</TD>
<TD>
<P>2[8]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2=336</P>
</TD>
<TD>
<P/>
<P>51</P>
</TD>
<TD>
<P/>
<P>338</P>
</TD>
<TD>
<P/>
<P>3[9]</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>338-2-3=333</P>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]Refers to both major and minor bleeding events. In this case I suggest not to report this outcome at 3 months.</P>
<P>[6]"8 (4 in each group) were considered not evaluable by the outcome adjudication committee" [6] (Applies to both arms)</P>
<P>[7]&#8220;Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4 percent) had major bleeding (P=0.27). The respective rates of any bleeding were 14 percent and 19 percent (P=0.09).&#8221;</P>
<P>[8]&#8220;Two patients in each group were excluded from the efficacy analysis because they did not have a qualifying thrombotic event: one patient had a thrombosis in an arm vein, one had an asymptomatic thrombus in the leg, and the other two did not have a confirmed pulmonary embolism&#8221;</P>
<P>[9]&#8220;Three patients assigned to oral anticoagulant therapy did not receive the study drug and were excluded from the safety analyses. Nineteen of 338 patients in the dalteparin group (6 percent) and 12 of 335 patients who received oral anticoagulant therapy (4 percent) had major bleeding&#8221;</P>
<TABLE COLS="14" ROWS="6">
<TR>
<TD COLSPAN="14" VALIGN="TOP">
<P>
<B>Outcome: Thrombocytopenia</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Study Name </B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>LMWH</B>
</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>UFH</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No most likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD[1]</P>
</TD>
<TD VALIGN="TOP">
<P>No with available outcome data (for CCA)[2]</P>
</TD>
<TD VALIGN="TOP">
<P>Events</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
<P>Rand</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No more likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No less likely to have MPD</P>
</TD>
<TD VALIGN="TOP">
<P>No. with available outcome data (for CCA)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt[3]</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt [4]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Pre-trt</P>
</TD>
<TD VALIGN="TOP">
<P>Post-trt</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hull 2006</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>100-1=99</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Meyer 2002</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4[5]</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>71-4=67</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>75-4=71</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>No: number; Rand: randomized; MPD: missing participant data; CCA: complete case analysis; Pre-trt: pre-treatment; Post-trt: post-treatment; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</P>
<P>[1]Participants reported as "non-compliant" (or "discontinued") to treatment for various reasons excluding "loss to follow-up", "withdrawal of consent", and "ineligible participants" (applies for both arms).</P>
<P>[2]Total number randomized - most likely MPD (pretreatment and post-treatment) (applies for both arms).</P>
<P>[3]Participants categorized as "ineligible" and did not receive first dose (applies for both arms).</P>
<P>[4]Participants categorized as "lost to follow-up", "withdrew consent", and "outcome not assessable" (applies for both arms).</P>
<P>[5]"8 (4 in each group) were considered not evaluable by the outcome adjudication committee" [5] (Applies to both arms)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies included in qualitative synthesis &lt;/p&gt;&lt;p&gt;(11 reports)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;65 full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9559 records screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9559 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;10,033 records identified through database searching&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;55 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9494 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;54 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;14 = unavailable data for cancer subgroup&lt;/p&gt;&lt;p&gt;1 = case series&lt;/p&gt;&lt;p&gt;15 = review&lt;/p&gt;&lt;p&gt;4 = retrospective study&lt;/p&gt;&lt;p&gt;2 = protocol&lt;/p&gt;&lt;p&gt;6 = observational study&lt;/p&gt;&lt;p&gt;4 = nonrandomized trial&lt;/p&gt;&lt;p&gt;4 = no cancer patients included&lt;/p&gt;&lt;p&gt;1 = only one cancer patient included&lt;/p&gt;&lt;p&gt;2 = no relevant outcome&lt;/p&gt;&lt;p&gt;1 = different durations of intervention&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>